

Journal Pre-proofs

Leveraging a multivariate approach towards enhanced development of direct compression extended release tablets

A.S. Sousa, J. Serra, C. Estevens, R. Costa, A.J. Ribeiro

PII: S0378-5173(23)00853-0
DOI: <https://doi.org/10.1016/j.ijpharm.2023.123432>
Reference: IJP 123432

To appear in: *International Journal of Pharmaceutics*

Received Date: 21 June 2023
Revised Date: 16 September 2023
Accepted Date: 19 September 2023

Please cite this article as: A.S. Sousa, J. Serra, C. Estevens, R. Costa, A.J. Ribeiro, Leveraging a multivariate approach towards enhanced development of direct compression extended release tablets, *International Journal of Pharmaceutics* (2023), doi: <https://doi.org/10.1016/j.ijpharm.2023.123432>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier B.V.



Leveraging a multivariate approach towards enhanced development of direct compression extended release tablets

Sousa, A.S.^{1,2}, Serra, J.², Estevens, C.², Costa, R.², Ribeiro, A.J.^{1,3*}

¹ Universidade de Coimbra, Faculdade de Farmácia, 3000-148 Coimbra, Portugal;

² Grupo Tecnimede, Quinta da Cerca, Caixaria, 2565-187 Dois Portos, Portugal;

³ i3S, IBMC, Rua Alfredo Allen, 4200-135 Porto, Portugal.

* Corresponding author:

António J. Ribeiro

Universidade de Coimbra

Faculdade de Farmácia, Portugal.

E-mail address: aribeiro@ff.uc.pt

1 Abstract

2 Extended release formulations play a crucial role in the pharmaceutical industry by
3 maintaining steady plasma levels, reducing side effects, and improving therapeutic
4 efficiency and compliance. One commonly used method to develop extended release
5 formulations is direct compression, which offers several advantages, such as simplicity,
6 time savings, and cost-effectiveness. However, successful direct compression-based
7 extended release formulations require careful assessment and an understanding of the
8 excipients' attributes. The scope of this work is the characterization of the compaction
9 behavior of some matrix-forming agents and diluents for the development of extended
10 release tablets. Fifteen excipients commonly used in extended release formulations were
11 evaluated for physical, compaction and tablet properties. Powder properties (e.g., particle
12 size, **flow properties**, bulk density) were evaluated and linked to the tablet's mechanical
13 properties in a fully integrated approach, and data were analyzed by constructing a
14 principal component analysis (PCA). **Significant variability was observed among the
15 various excipients. The present work successfully demonstrates the applicability of PCA
16 as an effective tool for comparative analysis, pattern and clustering recognition and
17 correlations** between excipients and their properties, **facilitating** the development and
18 manufacturing of direct compressible extended release formulations.

19 **Keywords**

20 Extended release; Excipient characterization; Direct compression; Multivariate data
21 analysis; Principal component analysis


22 **1. Introduction**

23 Excipients, once questioned about their functionality, are now recognized to play a central
24 role in the manufacture, stability and/or *in vitro* and *in vivo* performance of
25 pharmaceutical formulations. The diversity observed in pharmaceutical excipients, along
26 with their physicochemical properties and innate variability can have a significant effect
27 on the quality of the final drug product ([Thakkar et al., 2016](#)). It is acknowledged that a
28 given excipient can be used in different ways because its functionality is understood
29 according to specific drug product formulation and manufacturing ([Zhao et al., 2022](#)).
30 Recognizing the importance of assessing and controlling excipient functionality, both the
31 European Pharmacopeia (Ph. Eur.) and the United States Pharmacopeia (USP) have
32 adopted the concept of Functionality-Related Characteristics (FRCs). This concept
33 emphasizes the growing awareness of the importance of a systematic, scientific and risk-
34 based Quality by Design (QbD) approach, providing a comprehensive understanding of
35 excipient attributes for improved and controlled drug product quality throughout its
36 lifecycle ([Moreton, 2010](#)). A deep knowledge of FRCs, as critical material attributes
37 (CMAs), is crucial not only to support formulation development but also for evaluating
38 the potential effect of excipient variability on drug product quality. Accordingly,
39 excipients should be incorporated as an important part of the QbD design space, and their
40 variability needs to be built into the design space ([Carlin, 2018](#); [Kim and Choi, 2022a](#);
41 [Moreton, 2010](#)).

42 Oral extended release delivery systems have steadily increased in importance over the
43 years. It offers an opportunity to significantly improve patient compliance and therapeutic
44 outcomes. The complexity of oral extended release drug delivery systems development
45 makes the implementation of the **QbD framework, including risk assessment, design of
46 experiments (DoE) and multivariate data analysis (MVDA)**, essential to better understand
47 the product and process parameters ([Sousa et al., 2022](#)). **Generally, the simplest extended
48 release formulations, excluding the lubricant, consist of a ternary system comprising the
49 active pharmaceutical ingredient (API), matrix former polymer responsible for drug
50 release kinetics, and diluent ensuring rheological properties. The typical percentage of
51 polymer ranges from 20% to 50%, with the remaining percentage comprising the diluent
52 and API, depending on the dosage and manufacturing processing properties** ([Colombo et
53 al., 2008](#); [Maderuelo et al., 2011](#); [Timmings et al., 2014](#)). Studies have been carried out to
54 explore the effect of raw material properties on extended release matrix tablet
55 performance ([Maderuelo et al., 2011](#); [Thakkar et al., 2016](#); [Tobyn et al., 2018](#); [Vanza et
56 al., 2020](#); [Zhang et al., 2018](#); [Zhou et al., 2014](#)). Some of the most relevant FRCs of
57 polymers include molecular weight (MW) ([Vanza et al., 2020](#); [Zhou et al., 2014](#)),
58 viscosity ([Kosir et al., 2018](#); [Zhou et al., 2014](#)), hydration ([Vanza et al., 2020](#)), particle
59 size ([Haware et al., 2010](#); [Kosir et al., 2018](#); [Zhang et al., 2018](#)), powder flow ([Zhang et
60 al., 2019](#); [Zhang et al., 2018](#)) and degree of substitution of the polymer side chain
61 ([Caccavo et al., 2017](#); [Kosir et al., 2018](#); [Zhou et al., 2014](#)). Additionally, excipient
62 variability among different manufacturers, grades, batches and lots can significantly
63 affect the functionality and performance of extended release dosage forms ([Dave et al.,
64 2015](#); [Zhou et al., 2014](#)). To support the QbD approach and control raw material
65 variability, several studies are now using MVDA and/or artificial neural network (ANN)

66 ([Benedetti et al., 2019](#); [Haware et al., 2010](#); [Kim and Choi, 2022a, b](#); [Portier et al., 2021](#);
67 [Tobyn et al., 2018](#); [Wan et al., 2021](#); [Wang et al., 2020](#); [Zarmpi et al., 2020](#)); however,
68 only a small number have reported excipient variability for extended release formulations
69 ([Ilyes et al., 2021](#); [Kosir et al., 2018](#); [Zhang et al., 2018](#)).

70 Tablet manufacturing by direct compression represents a cost effective and relatively
71 simple approach for tablet manufacturing, as it comprises a minimal number of process
72 steps ([Alderborn and Nystrom, 1996](#)). Although the direct compression process has been
73 used routinely for more than a century, the development and maintenance of robust direct
74 compression processes requires a good knowledge and understanding of the interplay
75 between raw material properties ([Worku et al., 2017](#); [Yu et al., 2021b](#)), formulation
76 ([Dhondt et al., 2022](#)) and process parameters ([de Backere et al., 2022](#); [Grymonpre et al.,
77 2018](#)) to avoid potential problems during manufacturing. Several proposals towards
78 systematic approaches in tablet manufacturing have been made. The Manufacturing
79 Classification System (MCS) ([Leane et al., 2015](#)), the compression behavior
80 classification system ([Dai et al., 2019](#)) and the process classification maps linking API
81 physical properties and formulation to process parameters ([White et al., 2022](#)) were
82 developed and established for guiding and accelerating tablet formulation development
83 by direct compression. Typically, the process of direct compression includes raw material
84 blending, tableting (particle rearrangement, elastic and plastic deformation of particles,
85 fragmentation and formation of interparticulate bonds) and coating ([Alderborn and
86 Nystrom, 1996](#); [Carlin, 2008](#); [Lieberman and Lachman, 1989](#)). As the original properties
87 of the raw materials are not significantly modified during the direct compression process,
88 their intrinsic flow and compressibility can be limiting properties. When formulating
89 extended release direct compression tablets, the selection of the right combination of
90 excipients is extremely critical. It must fulfil certain criteria, including adequate density,
91 good powder flow properties and compressibility. There are numerous methods to
92 characterize the tableting behavior of powders. The principal material properties for the
93 characterization of tablet compression are compressibility, tableability and
94 compactibility, as outlined in the USP <1062> Tablet Compression Characterization.
95 These fundamental concepts capture the relationships among compaction pressure, tablet
96 porosity (ϵ) or solid fraction, and tablet tensile strength (σ) ([USP 40-NF 35, 2017](#)), as
97 illustrated in Fig. 1.



98

99 **Fig. 1.** USP <1062> tablet compression characterization based on the relationships
100 between tensile strength, solid fraction, and compaction pressure.

101 Since direct compression is **highly reliant on** API and excipient properties, the mitigation
102 of raw material-induced variability should be considered upstream of tablet
103 manufacturing. **Variability in MCC physical (e.g., ρ_{bulk} , ρ_{tapped} , particle size) and flow**
104 **properties can lead to different tablet mechanical properties (e.g., tensile strength),**
105 **functionality and manufacturability, thus resulting in undesired tablet quality (Zhao et al.,**
106 **2022).** By exploring and understanding the raw material- and process-related factors, i.e.,
107 establishing relationships between CMAs and critical process parameters (CPPs), it is
108 possible to establish and maximize tablet manufacturing process robustness. This
109 approach ensures that the production of tablets meets the required quality standards.

110 Previous studies attempted to extensively explore raw material properties linking them
111 with direct compression process performance and deploying predictive models for
112 formulation and process development (Bekaert et al., 2021; Escotet-Espinoza et al., 2018;
113 Hayashi et al., 2021; Yu et al., 2021b). Other studies have also correlated raw material
114 and blend properties with the process behavior via multivariate tools at different unit
115 operations of continuous direct compression manufacturing systems (e.g., feeding, die-
116 filling and compression steps) (Bekaert et al., 2021; Van Snick et al., 2018b; Van Snick
117 et al., 2019). Integrated pharmaceutical continuous manufacturing (CM) may be of
118 greater interest due to the potential use of process analytical technology for continuous
119 monitoring of CPPs as well as CQAs of raw materials and final drug products. This leads
120 to reduced production times and handling steps, improving the quality, efficiency and
121 flexibility of manufacturing (Vanhoorne and Vervaet, 2020). Van Snick et al. (2018a) and
122 their coworkers proposed a holistic material characterization approach and developed a
123 multivariate raw material property database of 55 pharmaceutical powders, **including a**
124 **wide variety of APIs and excipients**, that were characterized using a wide variety of
125 descriptors. Principal component analysis (PCA) was applied, which allowed the authors
126 to identify the critical material properties and support a rational selection of routine
127 characterization techniques. The developed material database can be key in successful
128 formulation design and predicting how a material behaves at each individual unit
129 operation. Dhondt et al. (2022) developed a data-driven platform linking raw material
130 properties, blend composition and process settings with tablet CQAs using the raw
131 material properties built by Van Snick et al. (2018a). Applying this model, it is possible
132 to improve the development process for new drug products and fine-tune the compaction
133 process settings. Although Van Snick's studies included a high quantity of excipients,
134 some of them used in extended release formulations such as HPC and/or HPMC, these
135 studies were not specifically designed for extended release formulation and did not
136 consider different matrix systems. Additionally, a recent study used PCA to evaluate the
137 behavior of different materials for direct compression. They focused on a wide range of
138 compression descriptors instead of the excipient type (Berkenkemper et al., 2023b).

139 **For extended release formulations, where controlled drug release is critical, accurate**
140 **control of tablet mechanical properties becomes even more significant to achieve and**
141 **does not compromise therapeutic efficacy. In the current paper, a holistic approach will**
142 **be implemented to study and understand how the raw material properties of different**
143 **extended release formulation-related excipients can impact manufacturability. Fifteen**
144 **excipients commonly used in extended release formulations, comprising matrix former**
145 **polymers and diluents, were selected to encompass a wide variety of material properties.**
146 **The materials selection took into account the combination of their availability, literature**
147 **review findings and prior knowledge. The compressibility, tabletability and**
148 **compactibility of the excipients were compared to facilitate their appropriate use in future**
149 **extended release matrix tablet development. Moreover, the most significant powder**

150 properties and mechanical parameters on tableting feasibility were identified by analyzing
151 data with different multivariate tools.

152 2. Materials and methods

153 2.1. Materials

154 The materials (15) included in this study were purchased from or provided by BASF
155 (Ludwigshafen, Germany), The Dow Chemical Company (Midland, MI, USA), Merck &
156 Co. (Kenilworth, New Jersey, USA), JRS Pharma (Rosenberg, Baden-Wurttemberg,
157 Germany), BENEIO (Mannheim, Baden-Wurttemberg, Germany), Avesta Pharma Pvt.
158 Ltd. (Mumbai, Maharashtra, India), Roquette (Lestrem, France), MEGGLE Pharma
159 (Wasserburg am Inn, Germany) and UNDESA (Barcelona, Spain). Table 1 provides an
160 overview of the raw materials. Chemical Abstracts Service (CAS) number and unique
161 ingredient identifier (UNII) were used as identifiers linked to the substance's molecular
162 structure or descriptive information.

163 **Table 1**

164 Raw materials used in the study, their function and manufacturer.

Abbreviation	Excipient name	Commercial name	Function	CAS N.	UNII	Manufacturer
KL-SR	Acetate polyvinyl 80% PVP 20%	Kollidon® SR	Matrix former	9003- 20-7 9003- 39-8	32K497ZK2U	BASF
HPMCK4M	Hydroxypropyl methylcellulose	Methocel™ K4M Premium	Matrix former	9004- 65-3	3NXW29V3WO	DuPont
HPMCK100	Hydroxypropyl methylcellulose	Methocel™ K100 Premium CR	Matrix former	9004- 65-3	3NXW29V3WO	DuPont
PEO-N750	Poly(ethylene)oxide	POLYOX™ WSR N750	Matrix former	25322- 68-3	4QIB4U4CQR	DuPont
PEO-1105	Poly(ethylene)oxide	POLYOX™ WSR 1105	Matrix former	25322- 68-3	16P9295IIL	DuPont
PEO-303	Poly(ethylene)oxide	POLYOX™ WSR 303	Matrix former	25322- 68-3	G3MS6M810Y	DuPont
PVA	Polyvinyl alcohol	Parteck® SRP80	Matrix former	9002- 89-5	532B59J990	Merck & Co.
RL	Lactose coprocessed	RetaLac®	Matrix former	5989- 81-1 9004- 65-3	EWQ57Q8I5X 39J80LT57T	MEGGLE
ADCP	Calcium hydrogen phosphate anhydrous	Emcompress® Anhydrous	Diluent	7757- 93-9	L11K75P92J	JRS Pharma
G721	Isomalt	galenIQ™ 721	Diluent	64519- 82-0	S870P55O2W	BENE0
TA-80	Lactose Monohydrate	Tabletose® 80	Diluent	64044- 51-5	EWQ57Q8I5X	MEGGLE

MD-IT12	Maltodextrin	Glucidex® IT 12	Diluent	9050-36-6	7CVR7L4A2D	Roquette
MAN-400DC	Mannitol	Pearlitol® 400 DC	Diluent	69-65-8	3OWL53L36A	Roquette
PEG6000	Poly(ethylene glycol) 6000	Macrogol 6000	Diluent	25322-68-3	30IQX730WE	Avesta Pharma
SMCCHD90	Silicified Microcrystalline Cellulose	PROSOLV® SMCC HD90	Diluent	9004-34-6	OP1R32D61U	JRS Pharma
MgSt	Magnesium stearate	Kemilub EM-F-V	Lubricant	557-04-0	70097M6I30	UNDESA

165 2.2. *Methods*

166 2.2.1. *Macroscopic material characterization methods*

167 2.2.1.1. *Laser diffraction*

168 Particle size distribution (PSD) of the raw material samples was performed by laser
 169 diffraction using a Horiba LA-960v2 Particle Size Analyzer - dry module. The powder
 170 was fed by a vibratory feeder to the dry cell of the light scattering instrument. Automatic
 171 control of the sample feed rate was set with an air pressure of 0.20 MPa, and each sample
 172 was measured in triplicate. A refractive index of 1.51 and transmittance range of 98.0%-
 173 95.0% (target T%=97.0%) were chosen. The statistical data were analyzed via Horiba
 174 LA-960 software. For each volumetric distribution, the 10th, 50th and 90th quantiles were
 175 reported as Dv10, Dv50 and Dv90, respectively. The width (dwidth) and span (dspan)
 176 were calculated to describe the PSD according to Eqs. (1) and (2):

$$177 \quad dwidth = Dv90 - Dv10 \quad (1)$$

$$179 \quad dspan = \frac{dwidth}{Dv50} \quad (2)$$

181 2.2.1.2. *Powder density and flow properties*

182 True density is a critical material attribute of powder materials since it is used to estimate
 183 tablet porosity and consequently compressibility and compactibility. The true density
 184 (ρ_{true}) of each excipient was measured using a helium pycnometer (AccuPyc 1330,
 185 Micromeritics®, USA). The measurements were performed with a cell of 10 cm³ at an
 186 equilibrium rate of 0.005 psig/min and a gas input pressure of 19.5 psi. The sample
 187 chamber was purged with 10 purging cycles followed by 5 measurement cycles. The true

188 density (g/cm^3) was determined by dividing the sample weight by the volume. The bulk
189 (ρ_{bulk}) and tapped density (ρ_{tapped}) of the powder particles were determined in accordance
190 with Ph.Eur. 2.9.3, using a 100 mL graduated cylinder mounted on a tapping device
191 (Erweka SVM, Tapped Density Tester, Heusenstamm, Germany). An exact mass of
192 powder was gently poured into the graduated cylinder. The initial volume and volume
193 after 1250 taps were recorded to calculate the ρ_{bulk} and ρ_{tapped} , respectively. The flow
194 properties of the powder were evaluated from the Hausner ratio (HR) and compressibility
195 index (CI). HR and CI were calculated according to Eqs. (3) and (4), respectively:

$$196 \quad HR = \frac{\rho_{\text{tapped}}}{\rho_{\text{bulk}}} \quad (3)$$

$$198 \quad CI (\%) = 100 \times \left(\frac{\rho_{\text{tapped}} - \rho_{\text{bulk}}}{\rho_{\text{tapped}}} \right) \quad (4)$$

200 2.2.1.3. Flow rate

201 The flow rate (FR) of the powder was determined using a granulate flow tester (GTB,
202 Erweka, Germany) with an 11.3 mm nozzle and a stirrer setting of 2. Approximately 30
203 g of material was poured into the 200 mL hopper. Material was allowed to flow through
204 the funnel orifice, and the flow rate was determined as the ratio of weight (g) to time
205 (seconds). The mean of three determinations was recorded.

206 2.2.1.4. Angle of repose

207 The flow properties of powder samples were assessed (in triplicate) by measuring the
208 angle of repose (AR) using a granulate flow tester (GTB, Erweka, Germany). The powder
209 (20 g) was poured into the funnel and allowed to flow through the hopper with a 10 mm
210 orifice diameter, forming a cone of powder. The sidewall of the built-up cone was
211 measured using an automatic laser, and the actual angle of repose was calculated.

212 2.2.1.5. Moisture gain

213 For determination of the moisture gain (MG) (%), the powder samples were taken in
214 separate Petri dishes and placed in a desiccator exposed at a temperature of $22 \pm 2^\circ\text{C}$ with
215 a relative humidity of approximately $75 \pm 2\%$. After 24 h, the percentage mass gained by
216 the samples was calculated.

217 2.2.2. Powder compression

218 Tablets were prepared by direct compression of lubricated excipients. All excipients were
219 manually passed through a sieve with a mesh size of $850 \mu\text{m}$. Each excipient was
220 lubricated with 1% w/w of magnesium stearate, previously sieved through a $250 \mu\text{m}$
221 mesh. To expedite the tableting process, a total of 20 g of each blend was mixed in a 75
222 mL HDPE wide-mouth bottle using a high-frequency agitator, CryoMill (Retsch), for 1
223 minute at 30 Hz. The compaction behavior of powder blends was evaluated using a single-
224 station compaction simulator (STYL'One Classic, Medel'Pharm, France). The simulator

225 was operated in displacement mode to simulate a S rotary press-TSM D compaction cycle
 226 with a pitch circle diameter of the turret of 370 mm. The compaction simulator was tooled
 227 with a standard EU-D 11.28 mm round flat-faced punch and die. To enhance the accuracy
 228 of the measurements, the impact of machine deformation was taken into consideration
 229 through the compression of an 11.3 mm stainless steel disk. Samples were prepared by
 230 manually pouring the weighed respective amount of powder (450 mg \pm 5% range) into
 231 the die, and a five-point compression profile was made from 25 MPa to 300 MPa. For
 232 PEO polymers, an additional shorter study was performed to a range of 25 MPa to 100
 233 MPa to better characterize their tableability and compactibility behavior (Al-Nasassrah
 234 et al., 1998; Yu et al., 2021a). To evaluate the dependence on compression speed, the
 235 powders were compressed at simulated compression speeds of 2 rpm and 80 rpm,
 236 corresponding to dwell times of 180-930 ms and 5-14 ms (time interval of 90% of force),
 237 respectively, depending on the excipient deformation behavior.

238 2.2.3. Tablet characterization

239 After ejection and a 24-hour relaxation period, the tablet thickness, diameter, crushing
 240 force, and weight were determined using a tablet tester (Smart-Test50, Sotax AG,
 241 Switzerland).

242 2.2.3.1. Tensile strength

243 Tensile strength (σ) constitutes a fundamental property of a compact and provides
 244 extremely useful information, as tablet crushing force is applicable to a single tablet size
 245 and shape. The tablet tensile strength (MPa) was calculated by Eq. (5) (Fell and Newton,
 246 1970), where F, d and T denote the crushing force (N), tablet diameter (mm) and tablet
 247 thickness (mm), respectively.

$$248 \quad \sigma = \frac{2F}{\pi dT} \quad (5)$$

250 2.2.3.2. Porosity

251 The tablet porosity (ϵ), as a descriptor of the structure of the compact or state of
 252 consolidation, was calculated by using the out-of-die characterization of the tablets
 253 according to Eq. (6):

$$254 \quad \epsilon = 1 - \frac{\rho_{\text{tablet}}}{\rho_{\text{true}}} \times 100 \quad (6)$$

256 where ρ_{tablet} denotes the apparent tablet density (g/mL), which was calculated by dividing
 257 the tablet mass by its volume. The solid fraction is the inverse of the porosity.

258 2.2.3.3. Mechanical properties

259 To gain a thorough qualitative understanding of the compression behavior of the studied
 260 formulations, plots illustrating compressibility, compactibility, and tableability were
 261 generated. Simultaneously, with the purpose of finding quantitative variables to

262 incorporate into PCA, some descriptors were assessed by widely used mathematical
263 models.

264 2.2.3.3.1. Compressibility

265 The compressibility of a material denotes the effect of compression pressure on the
266 porosity of compacts, i.e., how readily the material undergoes a change in volume (Sun,
267 2016). For describing tablet compressibility, different compression equations have been
268 proposed (Berkenkemper et al., 2023a). Of the several equations, the relationship
269 developed by Heckel (1961), which is based on the assumption that the porosity of the
270 tablet decreases with increasing pressure and follows first-order kinetics, is one of the
271 most well-known mathematical models. The Heckel analysis has been criticized due to
272 its known limitations, namely, the sensitivity to the true density, material deformation
273 behavior and experimental compaction conditions (Rue and Rees, 1978; Sonnergaard,
274 1999). Although it is the most established and widely used method for describing material
275 compressibility through its plasticity (Vreeman and Sun, 2021), it should be noted that a
276 binary approach classifying materials as brittle/ductile based on a single material
277 parameter can be insufficient, and a holistic approach should be applied considering
278 potential alternative mechanical metrics (Yost et al., 2022). Heckel analysis can be
279 applied either as an in-die or out-of-die method; however, the in-die method was found
280 to be a robust analysis, providing more accurate and reliable results (Berkenkemper and
281 Kleinbudde, 2022; Vreeman and Sun, 2021). The compression parameter derived from
282 Heckel analysis that indicates the plasticity of the material is the yield pressure (P_y),
283 calculated from Eq. (7):

$$284 \quad -\ln(\varepsilon) = \frac{1}{P_y}P + \alpha$$

285 (7)

286 where ε is the porosity of the tablet, P_y^{-1} is the slope of the linear portion of the Heckel
287 plot, P is the compression pressure, and α is the y-axis intercept. The Heckel equation
288 was fitted using data collected from in-die compaction at a maximum compaction
289 pressure of 300 MPa. Porosity was calculated using the in-die tablet thickness measured
290 by the displacement sensors of the compaction simulator, the true density and the out-of-
291 die tablet weight. The P_y was determined by linear regression of the linear region of the
292 Heckel plot using Analis software (Medelpharm, France). Qualitative assessment was
293 performed to select the most central part of the linear region with a coefficient of
294 determination set to at least 0.99.

295 2.2.3.3.2. Tableability

296 A tableability plot has been defined as a powdered material's ability to be transformed
297 into a tablet of a specific strength under a specific compression pressure (Sun, 2016). A
298 recent equation was proposed by Vreeman and Sun (2022b) to describe the tableability
299 of powders, i.e., the cause-effect relationship between the tablet tensile strength and the
300 applied compression pressure. The equation derived from the Ryshkewitch and Kuentz-
301 Leuenberger equations describes an asymmetric sigmoidal function and contains three
302 fitting constants (α , β and σ_{\max}) and the Lambert W function. Similarly, the Gompertz
303 function is also an asymmetric sigmoidal function that models exponential growth. A
304 comparison between these two equations in fitting tableability data was accessed.

305 Despite the superiority of the new equation for realistically describing tableability,
 306 Gompertz fittings are highly correlated with plasticity parameters ([Vreeman and Sun,
 307 2022b](#)). The tableability data were fitted by the 3P Gompertz function according to Eq.
 308 (8):

$$309 \quad TS = y_{max}e^{-e^{-b(P-c)}} \quad (8)$$

311 where y_{max} is the asymptotic value as the compression pressure (P) approaches infinity, b
 312 is a growth constant and c is the inflection point at the center of the curve where the
 313 convex curve becomes concave.

314 2.2.3.3.3. Compactibility

315 Compactibility describes the intrinsic relationship between tablet tensile strength and
 316 solid fraction and is related to the binding force between the particles as the compression
 317 pressure increases ([Osamura et al., 2016](#)). Typically, tablet tensile strength increases
 318 exponentially with solid fraction, as the increases in interparticle bonding strengthen a
 319 compact. The compactibility profiles of the investigated excipients were plotted by fitting
 320 the out-of-die porosity and tensile strength according to the Ryshkewitch-Duckworth
 321 equation ([Duckworth, 1953](#)):

$$322 \quad \ln(\sigma) = \sigma_0 - k_b \varepsilon \quad (9)$$

324 where σ is the tensile strength of the compact, ε is the porosity of the compacts, σ_0 is the
 325 theoretical maximal tensile strength of the compact at zero porosity, and k_b is the slope
 326 of the linear regression which represents the bonding capacity of the powder particles
 327 under increasing pressure. The values of the compactibility parameter (σ_0) and bonding
 328 capacity (k_b) obtained using the Ryshkewitch-Duckworth equation were determined for
 329 all studied excipients.

330 2.2.4. Compression analysis

331 2.2.4.1. Plastic and compression energy

332 Compression energy (E_c) is the energy given to the tablet during the compression phase
 333 when the compression force increases. The elastic energy (E_p) is the energy recovered
 334 from the tablet when the compression force decreases. Its value is reported negatively
 335 since the elastic recovery direction is opposite to the direction of the compaction force.
 336 Plastic energy is related to irreversible compression (e.g., plastic deformation) and
 337 corresponds to the sum of compression energy and elastic energy ([Bourduche et al., 2020](#);
 338 [Garekani et al., 2001](#)). Compaction raw data were produced, and E_c and E_p were
 339 automatically obtained according to the recorded force–displacement curve by the data
 340 acquisition software (Analis®, 2.08.5, Medelpharm, France).

341 2.2.4.2. In-die elastic recovery

342 In the initial compaction phase, the particles can undergo plastic and elastic deformation.
 343 When the compaction force is unloaded, the elastic deformation is recovered. During the

344 decomposition phase, many powders undergo elastic recovery, resulting in axial and
 345 radial expansion of the tablet (Picker, 2001). Excessive elastic recovery is prone to
 346 manufacturing defects, particularly capping (Vreeman and Sun, 2022a). Therefore, using
 347 elastic recovery as a key parameter for predicting the tendency of formulation to capping
 348 during drug product development would be a helpful approach from a pharmaceutical
 349 industry perspective to prevent future issues during the scale-up (Meynard et al., 2022b).
 350 The in-die elastic recovery (ER) of the tablets is defined as the percent increase in in-die
 351 tablet thickness when the axial pressure changes from the maximum value to zero. It is
 352 determined using Eq. (10), according to the method introduced by Armstrong and
 353 Hainesnu.Rf (1974).

$$354 \quad ER (\%) = \frac{h_t - h_0}{h_0} \times 100 \quad (10)$$

356 where h_0 is the corrected compression thickness at the maximum compression force (mm)
 357 and h_t is the in-die recovery thickness (mm). i.e., the distance between the punches when
 358 the force on the upper punch decreases to zero. The corrected compression thickness at
 359 maximum force is the exact value of the tablet thickness at maximum compression force
 360 after correcting for punch and machine deformation.

361 2.2.4.3. Ejection stress

362 The tablet ejection force is the force required to eject the tablet from a die after
 363 compression. It is mainly governed by the constraint of compact-die wall stress. The tablet
 364 ejection stress is the product of the compact-die wall friction coefficient and the residual
 365 die wall force stress upon tablet ejection. The ejection stress is calculated from the
 366 ejection force to account for the punch and die geometries. A higher ejection force is
 367 predicted for high radial die wall stress and can be associated with tablet defects such as
 368 capping and lamination (Uzondu et al., 2018). The ejection stress (MPa) is obtained from
 369 its maximum ejection force (EF), tablet diameter (d) and tablet thickness (T) as described
 370 in Eq. (11). The ejection force was measured and recorded during the compaction process
 371 with STYL'One Classic and Analis Software (Medelpharm, France).

$$372 \quad Ejection \ stress = \frac{EF}{\pi d T} \quad (11)$$

374 2.2.4.4. Strain-rate sensitivity

375 The strain rate sensitivity (SRS) measures the impact of the consolidation time and
 376 tableting speed on the deformation behavior of a material (Roberts and Rowe, 1985). The
 377 SRS of numerous pharmaceutical materials can directly affect the mechanical strength of
 378 tablets and subsequently impact the product quality attributes (Roopwani and Buckner,
 379 2021). A tableting plot for each excipient and compression speed was fitted with a
 380 Gompertz exponential function. A predicted tensile strength at a pressure of 150 MPa was
 381 used to evaluate the differences between tensile strength obtained at fast (σ_{fast}) and slow
 382 (σ_{slow}) compression speeds was normalized to tensile strength at slow compression speed
 383 using Eq. (12) For PEO polymers, the SRS was determined at 50 MPa.

$$SRS (\%) = \frac{\sigma_{fast} - \sigma_{slow}}{\sigma_{slow}} \times 100 \quad (12)$$

386

387 *2.2.5. Data analysis*


388 Data were analyzed via JMP® 17 (SAS Institute Inc., NC, USA) statistical analysis
389 software. Different statistical techniques were performed, such as distribution, scatterplot
390 matrix and PCA.

391 *2.2.5.1. Multivariate analysis*

392 PCA is a multivariate data analysis method used for reducing the dimensionality of a
393 dataset. PCA orthogonally transforms a high-dimensional set of observations of possibly
394 correlated variables into a new set of uncorrelated variables called principal components
395 (PCs). By reducing the dimensionality of the data, PCA can help to identify the most
396 important variables, key patterns, and relationships in a dataset. The first principal
397 component captures the most variance in the data, while each subsequent component
398 explains the next most variance, subject to being orthogonal to the previous components.
399 In the case of oral extended release delivery systems, PCA can potentially be used to
400 identify, evaluate and optimize input factors such as formulation or manufacturing
401 process variables that can affect drug product CQAs ([Sousa et al., 2022](#)).

402 **3. Results and discussion**403 *3.1. Raw material physical attributes*

404 The physical properties of the excipients were studied, including Dv10, Dv50, Dv90,
405 dspan, dwidth, ρ_{true} , ρ_{bulk} , ρ_{tapped} , FR, AR, CI, HR and MG. The volume-weighted PSD of
406 the investigated excipients is presented in Fig. 2. **Most of the PSD curves exhibit a mono-**
407 **modal distribution, although slight differences in the shape of the PSD curve are observed**
408 **among the excipients.** KL-SR, HPMCK4M, HPMCK100 and PVA had similar PSDs,
409 representing **smaller particle sizes covering a range of median particle sizes from 57.63**
410 **μm to 74.95 μm .** Powders with smaller particle sizes are more likely to be cohesive and
411 form aggregates, resulting in powder flow issues ([Allenspach et al., 2020](#)). In contrast,
412 **MAN-400DC showed a larger particle size, with a median particle size value of 393.17**
413 **μm .** The PSD expressed in span are in the range of 1.06 to 2.90. A lower span value
414 indicates a narrow particle size distribution and usually contributes to blend homogeneity.
415 **HPMCK4M had the highest span value (2.90), which can potentially lead to segregation**
416 **during tablet compression and, consequently, weight variability and poor content**
417 **uniformity.**



418

419 **Fig. 2.** Particle size analysis of the excipients: percentile values of Dv10, Dv50 and Dv90
 420 (a), dspan (b) and particle size distribution (c).

421 It is generally known that **flow behavior** can significantly affect the direct compression
 422 process as well as the CQAs of the drug product (e.g., weight and content uniformity).
 423 Accordingly, the **density and flow properties** of the excipients were examined, and a
 424 comprehensive overview of the obtained results is shown in Table 2. The bulk density of
 425 all excipients ranged between 0.274-0.720 g/cm³. The ρ_{tapped} was calculated and found to
 426 be between 0.371-0.844 g/cm³. ADCP, MAN-400DC and TA-80 exhibited the highest
 427 values of both ρ_{bulk} and ρ_{tapped} , while the lowest values were observed for RL,
 428 HPMCK4M, HPMCK100, MD-IT12 and KL-SR. The CI and HR were calculated from
 429 the ρ_{bulk} and ρ_{tapped} . Empirically, higher CI (> 25%) and HR (<1.34) values mean that the
 430 material is more cohesive and less able to flow freely. A CI of less than 15% and an HR
 431 of less than 1.18 have been used to indicate good **flow properties** since particles show
 432 little potential for further consolidation. The CI was found to be between 9.14 and 31.89%
 433 for all excipients. Similarly, HR values were noted in the range of 1.10 and 1.47. Almost
 434 all diluents showed CI and HR values lower than 15% and 1.20, respectively, indicating
 435 good compressibility properties. Otherwise, there is a substantial dispersion of CI and HR
 436 values in the case of polymers. According to the values shown in Table 2, good **flow**

437 **properties** were obtained for PEOs (PEO N-750, PEO-1105 and PEO-303) and KL-SR
 438 powders in this study. HPMCK4M, HPMCK100 and PVA showed the highest values of
 439 CI and HR. [Grdesic et al. \(2020\)](#) characterized the flow and compaction properties of
 440 different grades and suppliers of HPMC (type 2208), including K4M and K100M CR.
 441 The CI and HR values, even after the addition of magnesium stearate, showed poor to
 442 very poor flow properties. RL, a spray-dried coprocessed 50:50 HPMC:lactose blend,
 443 shows an intermediate flow with values of 25% for CI and 1.33 for HR, similar to the
 444 literature data ([Cirin-Varadan et al., 2022](#)).

445 A powder with good **flow properties** generally has a **higher** FR and lower AR. AR is an
 446 indirect method of qualifying powder **flow properties** because of its relationship with
 447 interparticle cohesion. According to the USP, an AR value less than 40° is a direct
 448 indicator of satisfactory powder **flow properties**. MAN-400DC, PEG6000 and ADCP
 449 exhibited higher FR values (16.858, 15.307 and 15.152 g/s, respectively) and lower AR
 450 values, as expected due to their high ρ_{bulk} and ρ_{tapped} . The larger particle size of MAN-
 451 400DC supports its superior free powder flow. HPMCK4M, HPMCK100 and PVA had
 452 poor free flow through the orifice with AR values above 40°. These results can explain
 453 the deterioration of the flow properties of extended release formulations with increasing
 454 additions of PVA ([Muzikova et al., 2018](#)).

455 **Table 2**

456 Raw material physical attributes of the excipients. Average values are shown \pm standard
 457 deviation ($\bar{x} \pm \text{SD}$).

Excipient	ρ_{true} [g/cm ³]	ρ_{bulk} [g/cm ³]	ρ_{tapped} [g/cm ³]	CI (%)	HR	FR [g/s]	AR [°]	MG (%)
KL-SR	1.227 (0.002)	0.388 (0.000)	0.447 (0.000)	13.25	1.15	2.887 (0.082)	25.533 (0.094)	0.539
HPMCK4M	1.336 (0.001)	0.323 (0.001)	0.469 (0.003)	31.09	1.45	3.271 (0.144)	40.433 (1.969)	0.692
HPMCK100	1.341 (0.000)	0.325 (0.004)	0.477 (0.004)	31.89	1.47	3.278 (0.096)	41.200 (0.980)	0.712
PEO-N750	1.251 (0.000)	0.413 (0.001)	0.462 (0.004)	10.62	1.12	9.036 (0.039)	16.667 (0.793)	0.090
PEO-1105	1.251 (0.001)	0.455 (0.003)	0.512 (0.004)	11.22	1.13	9.129 (0.306)	18.500 (0.216)	0.094

PEO-303	1.248 (0.000)	0.467 (0.003)	0.514 (0.005)	9.14	1.10	8.572 (0.069)	15.067 (0.736)	0.108
PVA	1.293 (0.000)	0.532 (0.000)	0.693 (0.006)	23.33	1.30	1.775 (0.071)	40.433 (1.461)	0.432
RL	1.449 (0.000)	0.274 (0.000)	0.371 (0.005)	26.03	1.35	6.188 (0.126)	30.667 (0.525)	0.341
ADCP	2.804 (0.003)	0.720 (0.003)	0.844 (0.001)	14.62	1.17	15.152 (0.000)	23.000 (0.707)	0.074
G721	1.498 (0.000)	0.411 (0.004)	0.475 (0.001)	13.54	1.16	9.840 (0.200)	23.533 (0.262)	0.027
TA-80	1.532 (0.001)	0.615 (0.007)	0.707 (0.001)	13.09	1.15	10.870 (0.096)	27.233 (0.918)	0.003
MD-IT12	1.366 (0.001)	0.361 (0.004)	0.425 (0.002)	14.89	1.18	7.774 (0.115)	29.333 (0.170)	0.460
MAN-400DC	1.492 (0.000)	0.658 (0.001)	0.776 (0.002)	15.27	1.18	16.858 (0.271)	21.800 (0.779)	0.023
PEG6000	1.242 (0.000)	0.544 (0.003)	0.615 (0.000)	11.65	1.13	15.307 (0.110)	22.467 (0.655)	0.048
SMCCHD90	1.555 (0.000)	0.446 (0.002)	0.526 (0.003)	15.20	1.18	5.553 (0.210)	21.467 (0.939)	0.199

458 3.2. Mechanical properties


459 The mechanical properties of the extended release formulation-based excipients were
 460 evaluated by comparing their compressibility, tableability and compactibility. The
 461 profiles are shown in Fig. 3, and the parameters derived from the applied mathematical
 462 models are described in Table 3. The analysis was conducted at a speed of 80 rpm,
 463 mimicking the high speed of industrial-scale rotary tablet presses in commercial
 464 manufacturing. The compressibility plots are depicted in Fig. 3a. There was no large

465 difference in the compressibility profiles among the excipients. Two stages can be
466 observed in the plot: an initial consolidation stage where the solid fraction increases
467 almost linearly with compaction pressure up to a solid fraction of approximately 0.8 and
468 a second stage where the tablet's solid fraction tends to achieve constant values, despite
469 the increasing compaction pressure. At this stage, the particles are forced to fill the void
470 spaces, resulting in no observed increase in the solid fraction. In general, higher solid
471 fraction values were obtained for diluents compared to polymers. ADCP is very difficult
472 to densify below a porosity of 0.3, even at the highest compaction pressure of 300 MPa
473 in this study, exhibiting the least reduction in porosity compared to the other diluents.
474 Additionally, ADCP and G721 show very poor plasticity and low compressibility
475 properties based on their high Py. On the other hand, the lowest Py of PEG6000 (15.5
476 MPa) indicates that less force is required to form a compact. PEG6000 exhibited a plastic
477 deformation, being more compressible and easier to form into a tablet. The molecular
478 weight (MW) and amount of PEG6000 can have a significant impact on tablet formulation
479 compressibility. Generally, lower PEG MW grades and higher concentrations tend to
480 have better compressibility ([Larhrib and Wells, 1998](#)). Among polymers, PEOs have the
481 highest solid fraction upon application of the lowest compaction pressure. The
482 compressibility profiles of PEOs with different molecular weights appeared to undergo
483 volume reduction to a similar extent, as described by ([Yu et al., 2021a](#)). The extent of
484 reduction in porosity did not appear to differ significantly between HPMCK4M,
485 HPMCK100, KL-SR and RL. The steep slope observed for these polymers' plots at the
486 lower compaction pressure values suggests lower resistance to volume reduction,
487 possibly correlated with their lower bulk density values compared to PEO polymers. It
488 should be noted that it was not possible to determine the solid fraction of PVA at lower
489 compaction pressures due to its weak structural integrity.

490 The tableability (Fig. 3b) of the excipients at 150 MPa follows the order KL-SR >
491 SMCCHD90 > G721 = HPMCK100 > HPMCK4M > MD-IT12 > RL > ADCP = MAN-
492 400DC > TA-80 > PVA > PEG6000. SMCCHD90 and KL-SR compacts showed the
493 highest increase in tensile strength of 9 MPa up to a compaction pressure of 200 MPa.
494 The steep increase in tensile strength at lower compaction pressure (e.g., 50 MPa) is due
495 to reduced tablet porosity caused by particle rearrangements and volume reduction,
496 resulting in an increased bonding area. This behavior is typically seen with plastic
497 deforming materials ([Hentzschel et al., 2012](#)). PEO polymers also seem to have good
498 tableability behavior with tensile strength values higher than 2 MPa and higher values of
499 growth rate (b). As a general rule of thumb, 1.7 – 2.0 MPa is considered the minimum
500 value of tensile strength to obtain mechanically strong tablets to withstand commercial
501 manufacture and packaging ([Pitt and Heasley, 2013](#)). However, the high degree of plastic
502 deformation of PEO ([Yang et al., 1996](#)) polymers, characterized by their ability to deform
503 permanently, makes it impossible to determine the tablet resistance to crushing at lower
504 porosity values, as the compact deformed (volume reduction) instead of failed in tension
505 ([Al-Nasassrah et al., 1998](#); [Podczeck, 2012](#)), exceeding the measuring range of the
506 hardness tester (maximum 800 N). Therefore, the tableability and compactibility plots of
507 PEO polymers are produced below 100 MPa of compression pressure. Comparing the
508 tableability profiles of both HPMC, HPMCK100 shows superior tableability, as reported
509 by [Grdesic et al. \(2020\)](#). Additionally, particle size and moisture content have been shown
510 to affect the mechanical strength of tablets. A small particle size of plastically deformed
511 materials allows for a high surface area for bonding, resulting in increased tensile strength
512 at lower compression pressure. However, at higher values of compression pressure (> 150
513 MPa), the tensile strength of both HPMCs reaches a plateau, assuming an asymptotic

514 profile. This behavior can be explained by the high moisture content values present in
515 HPMC polymers that may have a plasticizer effect. Therefore, the tensile strength reaches
516 a maximum and may start decreasing. The choice of HPMC grades significantly impacts
517 tableability and compactibility profiles, with higher degrees of substitution leading to
518 improved tableability and compactibility due to an increased number of contact points
519 between particles in the matrix tablet (Ghori, 2016). On the other hand, PVA and
520 PEG6000 exhibit poorer tableability, as evidenced by lower values of the Gompertz
521 function asymptote (c). Even under high compression pressures, the tensile strength
522 remains below 2.0 MPa.

523 The compactibility profiles are shown in Fig. 3c and Table 3. Except for ADCP, at a solid
524 fraction of 0.8, the compactibility profile was ranked in a similar order to the tableability
525 profile. For all investigated excipients, the compactibility profiles can be well described
526 using the Ryshkewitch-Duckworth parameters (σ_0 and k_b). The correlation coefficients
527 (R^2) of the Ryshkewitch-Duckworth equation, obtained using nonlinear regression
528 analysis, were above 0.999, exhibiting a good correlation between the tensile strength and
529 compact porosity. ADCP yielded the highest value of the compactibility parameter, σ_0 ,
530 of 459.591 MPa, which decreased significantly to 1.175 MPa in the case of PEG6000.
531 The value of k_b follows the order TA-80 > ADCP > PVA > MAN-400DC > RL > PEO-
532 1105 > G721 > PEO N-750 > PEO-303 > HPMCK100 > KL-SR > HPMCK4M >
533 PEG6000 > MD-IT12 > SMCCHD90. Higher k_b values suggest a stronger bonding
534 capacity between the particles, implying a rapid increase in tablet tensile strength with
535 decreasing porosity.



536

537 **Fig. 3.** Compressibility (a), tableability (b) and compactibility (c) profiles of the
 538 investigated excipients at 80 rpm. The solid lines and markers represent the polymers and
 539 the open markers and dashed lines represent the diluents.

540 **Table 3**541 **Model parameters and R² values for the fit of the compression data at 80 rpm according to**
542 **Heckel, Gompertz and Ryshkewitch-Duckworth equations.**

Excipient	Compressibility - Heckel equation		Tabletability Gompertz function				Compactibility Ryshkewitch-Duckworth equation		
	Py (MPa)	R ²	α	b	c	R ²	σ_0 (MPa)	k _b	R ²
KL-SR	53.4	0.991	9.250	0.029	67.765	0.999	32.379	8.748	0.999
HPMCK4M	53.0	0.993	3.046	0.033	50.179	0.989	12.664	8.747	1.000
HPMCK100	56.3	0.991	4.221	0.023	49.742	0.999	15.541	8.903	1.000
PEO-N750	46.7	0.990	4.212	0.029	34.323	0.987	12.530	9.272	1.000
PEO-1105	44.4	0.993	2.891	0.038	34.390	0.984	11.662	9.617	1.000
PEO-303	42.4	0.994	2.386	0.055	28.073	0.998	10.474	9.181	1.000
PVA	91.2	0.991	1.623	0.018	110.545	1.000	15.739	14.218	1.000
RL	63.3	0.994	3.078	0.014	94.397	0.994	11.666	10.500	1.000
ADCP	706.7	0.998	7.109	0.007	237.648	0.998	459.591	14.934	1.000
G721	817.0	0.995	9.152	0.009	150.364	0.983	3.487	9.609	1.000
TA-80	170.9	0.998	6.653	0.006	260.027	1.000	12.526	18.342	1.000
MD-IT12	817	0.995	3.224	0.020	91.874	0.999	3.487	7.208	1.000
MAN-400DC	148	0.999	3.450	0.008	160.358	0.998	5.027	13.736	1.000
PEG6000	15.5	0.991	0.528	0.047	30.411	0.985	1.175	8.693	1.000

543 3.3. Relationships among powder and compression descriptors


544 The evaluation of the behavior of various powders under **compaction** pressure involved
545 the determination of a **large number of** descriptors representing the bulk properties of
546 **powder excipients, compression process and tablet attributes**. This study provides a
547 complete dataset, presented in Supplementary Material. **The relationship between the**
548 **measured variables from the above experiments can be investigated by performing a**
549 **correlation analysis on a one-to-one basis using a scatterplot matrix**. It should be noted
550 that correlating flow properties of excipients with their plastic deformation during tablet
551 process can provide significant challenges. This may be attributable to multivariate
552 factors impacting the compressibility behavior. A preliminary analysis was performed to
553 assess the main correlations between the studied variables. Among the parameters
554 included in the analysis, those that are theoretically correlated with each other (e.g., Dv10,
555 Dv50, Dv90) and those whose correlation coefficient was between -0.6 and 0.6 were
556 excluded. Fig. 4 shows the scatterplot matrix of the experimental data at 80 rpm
557 customized with density ellipses and significance circles. **The ellipses show a 95%**
558 **bivariate normal confidence density ellipse in each scatterplot**. The blue significance
559 circles show the correlations, with dark blue indicating a strong positive relationship
560 between the pairwise variables. Each marker represents one excipient at a given
561 compression pressure.

562 Some powder bulk physical properties were mutually correlated. Dv50 is negatively
563 correlated with dspan and positively correlated with FR. A negative correlation between
564 Dv50 and dspan indicates that larger particles tend to have a narrower distribution,
565 resulting in a smaller dspan. FR exhibits a positive correlation with Dv50 and ρ_{bulk} and,
566 as expected, a strong negative correlation with AR, CI and MG. Moisture can lead to
567 agglomeration or cohesive behavior between particles, decreasing the flow properties. A
568 positive correlation between FR, Dv50 and ρ_{bulk} suggests that powders with higher density
569 and median particle size tend to have better flow properties. The specific surface area
570 decreases with increasing particle size, resulting in improved flow properties.

571 **Correlations between powder attributes and compression-related descriptors were also**
572 **found**. Plastic (E_p) and compression energy (E_c) showed a positive correlation with
573 compression pressure (P) and tensile strength (σ). The E_p of a material is related to its
574 ability to undergo plastic deformation, which is an irreversible change during
575 decompression. In reality, higher compression pressures can result in higher plastic
576 energy absorption, as depicted by a typical stress–strain curve.

577 High correlations were also observed between ER and flow-related parameters (FR, AR
578 and CI). While these are interrelated parameters that reflect how the physical properties
579 of the powder can influence the tablet compression process, they are typically evaluated
580 independently. ER integrates the elastic expansion of the tablet during the decompression
581 phase and should be minimized to avoid manufacturing defects such as capping. **A**
582 **relationship was also observed between the compactibility descriptors derived from the**
583 **Ryshkewitch-Duckworth equation (k_b and σ_0) and the density parameters**. The density
584 ellipse relating ρ_{true} and σ_0 is narrow and has a steep slope, suggesting a strong correlation
585 between these variables. Compactibility, which describes tensile strength as a function of

586 solid fraction, suggests that materials with higher ρ_{true} may have stronger interparticle
 587 bonds, resulting in higher tensile strength. It is worth noting that while several powder
 588 and tablet attributes were shown to be correlated with each other, in some cases, no
 589 significant correlations were observed, justifying the diverse set of excipient bulk and
 590 mechanical properties provided by the dataset.



591

592 **Fig. 4.** Scatterplot matrix of excipient variables. The red ellipses indicate the 95%
 593 confidence density ellipses. The blue significance circles show the correlations. Each
 594 marker represents one excipient at a given compaction pressure at 80 rpm.

595 3.4. Principal component analysis

596 PCA was performed on the powder and tablet property data matrix to explore and
 597 highlight the variance within the input dataset. Typically, PCA transforms the input data
 598 into a lower dimensional set of new independent variables known as principal
 599 components (PCs). This transformation allows the capture of the highest possible
 600 variance. The loading scatter plot derived from PCA displays the spatial distribution of
 601 variables influenced by two primary PCs, which explained most variations in the data.
 602 Conversely, the score plot reveals details about the diversity among the samples, enabling
 603 discrimination of the similarities or differences between samples. When variables are
 604 highly positively correlated with each other, they are positioned in similar directions or
 605 closer to each other on the loading scatter plot. In contrast, the variables are negatively
 606 correlated when they are located on opposite sides of the plot origin. The correlation is

607 considered weaker when the descriptor is close to the origin of the loading scatter plot,
 608 which is not relevant for the respective PCs. The rows on the dataset related to PEO and
 609 PVA where tensile strength was not measurable were not considered for PCA. Once
 610 again, to make the analysis more representative of commercial scale tableting operations,
 611 a speed of 80 rpm was selected.

612 **Table 4**


613 Input variables incorporated in PCA.

PCA input variables	Symbol
Particle size	Dv10, Dv50, Dv90, dwidth and dspan
Density	ρ_{true} , ρ_{bulk} , ρ_{tapped}
Flow properties	HR, CI
Flow rate	FR
Angle of repose	AR
Compression pressure	P
Tensile strength	σ
Porosity	ϵ
Compressibility	P_y
Compactibility	σ_0 , k_b
Tabletability	b, y_{max}
Plastic energy	E_p
Compression energy	E_c
Elastic recovery	ER
Ejection stress	ES

Strain rate sensitivity SRS


Moisture gain MG

614 Fig. 6 shows the loading scatter plot (left) and the score plot (right) of the PCA of the
 615 selected data matrix composed of all studied excipients with 26 variables (Table 4). The
 616 most common method of selecting the principal components to be used is to set a
 617 threshold of cumulative explained variance. The suitability of PCA for dimension
 618 reduction can be considered when few principal components are sufficient to explain a
 619 significant part of the variance in the data. The scree plot (Fig. 5), where the percentage
 620 of the cumulative variance is explained, shows that the first four principal components
 621 explained approximately 80% of the total variation, of which the contributions of the first
 622 two components to the total variance were 33.2% and 20.2%, respectively, as displayed
 623 in Fig. 6.




624

625 **Fig. 5.** PCA scree plot and percentage of the cumulative variance in the data.



626

627 **Fig. 6.** PCA based on the first two components: (a) loading scatter plot and (b) score
 628 scatter plot. The colored areas indicate the 95% confidence ellipses.



629

630 **Fig. 7.** Plot of partial contribution of excipient variables on PCA.

631 The loading scatter plot describes the contribution of each of the original variables
 632 included in the PCA (Fig. 6a). By plotting the loadings for the two PCs, it is possible to
 633 assess the relative importance of each of the variables and demonstrate how these
 634 properties influence the orientation of excipients' location on the plane. As depicted in
 635 Fig. 7, the variability of PC1 was mainly dominated by the bulk properties of powders
 636 and ER. The second PC was predominantly affected by tableting variables, with SRS,
 637 tableting growth rate (b) and ρ_{true} showing the highest weight.

638 In the first principal component (PC1), it can be observed that FR is positioned to the
 639 right side of the loading scatter plot, exhibiting strong positive PC1 loading values.
 640 Conversely, HR, CI, and AR, which collectively describe the propensity of powders to
 641 be compressed, exhibit high negative PC1 loadings and are grouped together. Powders
 642 with higher CI and HR, indicating poorer flow properties and greater cohesiveness, have
 643 a higher AR and lower FR. These high negative PC1 loadings are clustered with MG and
 644 ER, suggesting that poorly flowing excipients with higher moisture content will have a
 645 relatively higher degree of expansion during the decompression phase. Moreover,
 646 moisture absorption can result in strong cohesion between particles, higher densification,
 647 and a consequent decrease in flow properties (Zhang et al., 2003). Additionally, the
 648 increase in ER may be attributable to the high moisture content due to the modification
 649 of the deformation behavior of the excipient. The ρ_{bulk} and ρ_{tapped} were also located on the
 650 positive side of PC1 and were opposite to the flow parameters (CI, HR, AR), as reported
 651 in the literature (Kim and Choi, 2022a; Wan et al., 2021). This result elucidates that
 652 materials with higher density tend to have better flow properties. Nevertheless, there are
 653 dominant forces acting on particles (gravitational, friction, adhesive and cohesive), and
 654 the mechanisms of interaction between them define flow characteristics. Moreover, the
 655 relationship between the forces and powder flow behavior is governed by a combination
 656 of several powder characteristics, such as particle size distribution, density, shape, surface
 657 properties and moisture content, and therefore should be mutually assessed (Clayton,
 658 2019; Podczek, 1998). In our understanding and according to the powder deformation
 659 process, there is no causal relationship between flow properties and ER. The particle size
 660 descriptors (Dv10, Dv50, Dv90 and dwidth) were grouped together in the lower right


661 corner (i.e., at higher PC1 and negative PC2 loadings), slightly opposite of the dspan, as
662 illustrated by [Dai et al. \(2019\)](#). Particle size and flow descriptors were also negatively
663 related. As expected, larger particles generally flow better, presenting lower values of CI
664 and HR ([Wan et al., 2021](#)).

665 The loading scatter plot indicates positive PC2 loadings for ρ_{true} , σ_0 , ES, y_{max} , E_p and E_c .
666 Notably, as E_p corresponds to the total energy given to the tablet, it includes E_c , i.e., the
667 energy given to the tablet when the force increases. Furthermore, E_p increases with
668 increasing compression pressure because of the greater extent of particle deformation.
669 Additionally, it is reasonably expected that the higher the energy given to the tablet during
670 compression, the greater the σ ($R^2 = 0.802$). Although ϵ shows an insignificantly smaller
671 weighting, the assessment of PC2 against PC3 (accounting for 14.9% of the overall
672 variance) demonstrated a strong negative PC3 loading for ϵ (data not shown). P and ϵ are
673 inversely related; as the tablet compression pressure increases, the particles become more
674 compact, reducing the void spaces between them and decreasing the porosity ([Jin et al.,
675 2022](#)).

676 The growth constant rate of the Gompertz equation (b), a reasonable predictor of material
677 plasticity, showed high negative PC2 loadings in the opposite direction of y_{max} . Higher b
678 values suggest a decrease in y_{max} . This y_{max} position also suggested that powders with a
679 higher density tend to require higher pressure to form a structure exhibiting appreciable
680 mechanical strength. This was already described by [Dai et al. \(2019\)](#), where tabletability
681 was positively correlated with tensile strength and negatively correlated with density
682 parameters. ES and P_y , although partially explained by PC1 and PC2, are positively
683 related. One possible explanation for this is associated with brittle materials that exhibit
684 a higher degree of nonelastic deformation during loading. Strong plastic deformation
685 reflects a higher residual radial die wall stress and, consequently, higher tablet ejection
686 force ([Takeuchi et al., 2004](#); [Uzundu et al., 2018](#)), which could lead to capping or
687 lamination ([Paul and Sun, 2017](#)). [Meynard et al. \(2022b\)](#) developed a machine learning
688 predictive model (decision tree classification) of capping behavior from three in-die tablet
689 properties: the plastic energy, the in-die elastic recovery and the residual die-wall
690 pressure. High values of plastic energy and low values of the in-die elastic recovery and
691 residual die-wall pressure were related to formulations giving noncapped tablets. P_y is
692 also moderately anti-correlated with moisture content, possibly due to plastic materials
693 with low yield pressure containing a significant moisture content. In HPMC, a
694 hygroscopic material, moisture acts as a plasticizer, resulting in lower porosity and thus
695 better compressibility ([Nokhodchi et al., 1996](#)). The compactibility of each excipient was
696 fitted using the Ryshkewitch–Duckworth exponential equation, where the bonding
697 capacity constant (k_b) and σ_0 were obtained. As expected, compactibility parameters are
698 positively related to each other and positioned in the right upper corner of PCA, being
699 moderately explained by PC2, similar to σ .

700 From the score scatter plot (Fig. 6b), two main clusters can be identified based on
701 excipient function. Matrix former excipients are mostly distributed in the left half of the
702 scatter plot, whereas the diluents are located on the right side, mainly explained by PC2.
703 The hygroscopic nature of polymers, their ability to swell and the presence of amorphous
704 regions can play a significant role in the diffusion of water molecules into the polymer,
705 explaining the strong negative loading of MG on PC1. The predominant plastic
706 deformation mechanism of polymers contributes to an increased mechanical strength
707 under a given compression pressure, higher in-die ER and lower P_y compared to diluents,
708 as observed by the distinct positions of these variables on the loading plot. Otherwise,

709 while polymers act as a matrix system in formulations for extended release, the diluents
 710 chosen depend on the type of formulation and manufacturing process. Diluents used in
 711 direct compression formulations can have a variety of chemical nature and functional
 712 properties, and their intended use may differ depending on the type of formulation under
 713 development, justifying their widespread distribution along the PC2 axis. Nonetheless,
 714 diluents are positioned more on the right side, validating their high flow properties and
 715 large particle size, which provide ideal conditions for direct compression.



716

717 **Fig. 8.** PCA biplot of excipient samples and explanatory variables - PC2 against PC1.

718 The PCA biplot, illustrated in Fig. 8, displays the correlation scaled loading and score
 719 vectors from both variables and samples into a single plot presenting how all excipients
 720 are distributed based on how each of the variables contributes to the first two principal
 721 components. The data points are represented as colored signs whereby each excipient is
 722 displayed in one color. The loading of the input variables is represented by red lines and
 723 black points. Excipients were scattered in all quartiles of the plot, and the samples with
 724 the most similar properties were clustered together. In contrast, excipients with notably
 725 contrasting descriptors will typically be positioned at opposite sides.

726 Evaluating the biplot, the flow behavior can be qualitatively predicted based on the
 727 correlation between excipients and their properties. The desirable trend of flow behavior
 728 is much more dependent on PC1 than PC2. For example, excipients on the **negative**
 729 side of PC1 have lower ρ_{bulk} and ρ_{tapped} , higher CI and HR and higher cohesion, indicating that
 730 these powders are poorly flowing. HPMCK4M, HPMCK100 and PVA were located on

731 the left side of the PC1 vs PC2 score scatter plot. These materials have lower flow
732 properties, as demonstrated by higher values of CI and HR as well as lower values of FR.
733 [Allenspach et al. \(2020\)](#) investigated the flow behavior of HPMCK4M, showing high CI
734 values and very low FR values, consistent with the obtained results. With improved flow
735 of the direct compression HPMC grades, it would be more feasible to use these excipients
736 in direct compression manufacturing. The highest flowability was expected for KL-SR,
737 resulting from lower HR and CI values. The smaller particle size and higher MG most
738 likely cause high cohesiveness, which affects flow properties ([Hauschild and Picker-
739 Freyer, 2006](#)) and results in the KL-SR samples plotted in the upper left corner. ADCP,
740 MAN-400DC, G721 and TA-80, with CI lower than 16%, fell on the right, based on the
741 loading plot. These diluents with brittle-predominant deformation usually exhibit high
742 density and excellent flow properties. These results were consistent with the literature
743 ([Bolhuis et al., 2009](#); [Haware et al., 2009](#); [Ilic et al., 2009](#)). Similar patterns were observed
744 in scatter plot PCA by [Berkenkemper et al. \(2023b\)](#) and [Van Snick et al. \(2018a\)](#), where
745 TA-80 is positioned near density descriptors. During tablet compression, brittle materials
746 present high Py and ES ([Ilic et al., 2013](#); [Michaut et al., 2010](#)), which explains their same
747 side and direction along the coordinate axis of PCs. In our analysis, the Py of brittle
748 materials was found to be significantly higher than that of plastic materials. Overall, the
749 order of powder yield pressure at 80 rpm is MD-IT12 (817.0 MPa) > ADCP (706.7 MPa)
750 > TA-80 (170.9 MPa) > MAN-400DC (148.0 MPa) > G721 (102.0 MPa). The Heckel
751 analysis reported in the literature also supports these findings, as a low slope of the linear
752 portion of the compression curve was found for ADCP with a Py value significantly
753 higher than that of silicified microcrystalline cellulose, confirming the plastic
754 deformation behavior of the latter and brittle fracture of the former ([Hentzschel et al.,
755 2012](#)). KL-SR, PEOs, and PEG6000, despite their plastic behavior, exhibited slightly
756 more positive scores along PC1, as their flow properties are substantially better than those
757 of other polymers. Furthermore, both PEO and PEG6000 have low melting points, which
758 could potentially lead to an increase in ejection force during tablet compression and
759 contribute to a higher likelihood of sticking ([Meruva and Donovan, 2019](#)). SRS was
760 located on the far lower side of the loading scatter plot, suggesting a strong negative
761 correlation with PC2. Speed-dependent friction ([Desbois et al., 2022](#)), viscoplasticity
762 ([David and Augsburg, 1977](#)), viscoelasticity ([Meynard et al., 2022a](#)) or air entrapment
763 ([Casahoursat et al., 1988](#)) are phenomena that can be involved in SRS. Low SRS is
764 desirable, if less sensitivity to an eventual change in tableting speed on scale-up is a
765 concern. Generally, polymeric materials known to deform plastically require more time
766 to consolidate, making them more sensitive to speed variations ([Roberts and Rowe,
767 1985](#)). Therefore, the position of PEO polymers and PEG6000 on the score plot is
768 reasonably understood. Density parameters show a negative correlation with the growth
769 rate (b) descriptor from the Gompertz function. Powders that have a high density, such as
770 ADCP, TA-80 and MAN-400DC ($\rho_{\text{bulk}} > 0.6 \text{ g/cm}^3$), show an apparently linear
771 progression of tensile strength over the pressure studied. [Thoorens et al. \(2015\)](#) studied
772 the impact of microcrystalline cellulose physicochemical properties on tabletability,
773 suggesting that ρ_{tapped} is negatively correlated with the tensile strength at 85 MPa
774 compaction pressure. The k_b for brittle materials was higher and according to previously
775 reported values ([Jonat et al., 2005](#); [Reynolds et al., 2017](#)), suggesting a high capacity to
776 create new bonds and, hence, to increase the mechanical resistance of tablets. In fact,
777 brittle materials that experience extensive particle fragmentation during compression
778 typically yield tablets with high tensile strength, even at significantly high porosity (e.g.,
779 0.3-0.4). This is attributable to the increased bonding contact area ([Patel et al., 2006](#);
780 [Reynolds et al., 2017](#)). For the coprocessed excipient, RL, a less significant weighting

781 was found on PC1 and PC2, thus appearing in the center of the TA-80 and HPMC
782 polymers. MAN-400DC is located on the right side of the biplot and exhibits strong
783 positive PC1 loading values, certainly due to its higher particle size.

Journal Pre-proofs

784 **4. Conclusion**

785 The present work provides insight into and enhances our understanding of bulk properties
786 and tablet compression behavior of 15 different excipients commonly employed in the
787 development and manufacturing of extended release tablets. The physical and mechanical
788 properties of these materials were carefully characterized in terms of particle size
789 distribution, flow properties, moisture gain, compression and sensitivity to compression
790 speed. The relationships between tablet porosity, tensile strength and compaction pressure
791 were used to evaluate tableability, compactibility and compressibility. There was no
792 significant difference in the compressibility profiles of the majority of the studied
793 excipients. ADCP showed to be weakly compressible because it was extremely difficult
794 to densify below a porosity of 0.3. All excipients exhibited a decrease in compact porosity
795 with increasing compression pressure. The highest tableability and compactibility were
796 determined for KL-SR and SMCCHD90. Otherwise, PVA and PEG6000 demonstrated
797 the lowest tableability with tensile strength values below 2.0 MPa. PCA was applied to
798 project excipient properties onto reduced dimensions and facilitate a thorough
799 understanding of the dataset, providing valuable insights into the correlations among the
800 variables. Two different groups of materials - diluents and polymers - could be clearly
801 distinguished on the score plot of PCA. They differed markedly in their consolidation
802 behavior and plasticity during the compression process. It was found that MAN-400DC,
803 ADCP and TA-80 were suitable diluents for direct compression due to their superior
804 flowability and tableability. In relation to matrix formers, the results indicated that the
805 various grades of PEO display similar and favorable flow and tableting characteristics.
806 FR, MG, ER, and SRS were identified as having the most significant impact on the PCA
807 loadings. The mean yield pressure, P_y , obtained from the Heckel analysis, along with the
808 Ryshkewitch-Duckworth parameters (σ_0 and k_b), were observed to exhibit a positive
809 correlation with ES and thus provide an important information on excipient deformation
810 behavior. By identifying the key excipient variables, it is possible to focus efforts on
811 controlling or optimizing extended release formulation-related excipients to minimize
812 variability. Finally, it is crucial to consider the role of the API, additional excipients, and
813 physical interactions between them in the tablet formulation workflow. The results also
814 suggest further employing QbD tools, such as risk assessment or DoE, to assess how
815 formulation variables (e.g., polymer amount, compression pressure) affect drug product
816 compaction behavior. In summary, this study offers additional insights into how the
817 physical properties of various excipients influence the quality attributes of tablets.
818 Because commercial scale tableting operations can be hampered by poorly characterized
819 raw material properties, this work is considered a useful tool for limiting resource
820 consumption in early drug product development, ultimately saving time and resources.

821 **CRedit authorship contribution statement**

822 **Ana Sofia Sousa:** Conceptualization, methodology, investigation, writing – original
823 draft, Visualization. **João Serra:** Conceptualization, supervision. **Catarina Estevens:**
824 Writing – review & editing. **Ricardo Costa:** Conceptualization, Writing – review &
825 editing. **António José Ribeiro:** Conceptualization, writing – review & editing,
826 supervision.

827 **Declaration of Competing Interest**

828 The authors declare that they have no known competing financial interests or personal
829 relationships that could have appeared to influence the work reported in this paper.

830 **Acknowledgments**

831 Ana Sofia Sousa acknowledges the PhD grant PD/BDE/150736/2020, assigned by FCT
832 (Fundação para a Ciência e Tecnologia, Portugal) and the Tecnimede Group from Drugs
833 R&D Doctoral Program.

834 **Appendix A. Supplementary material**

835 Supplementary data for this article can be found online at

836 **Data availability**

837 Data will be made available on request.

838 **References**

- 839 Al-Nasassrah, M.A., Podczeck, F., Newton, J.M., 1998. The effect of an increase in chain length
840 on the mechanical properties of polyethylene glycols. *Eur. J. Pharm. Biopharm.* 46, 31-38.
841 [https://doi.org/10.1016/s0939-6411\(97\)00151-3](https://doi.org/10.1016/s0939-6411(97)00151-3).
- 842 Alderborn, G., Nystrom, C., 1996. *Pharmaceutical powder compaction technology*. Marcel
843 Dekker, Inc., New York.
- 844 Allenspach, C., Timmins, P., Sharif, S., Minko, T., 2020. Characterization of a novel
845 hydroxypropyl methylcellulose (HPMC) direct compression grade excipient for pharmaceutical
846 tablets. *Int. J. Pharm.* 583, 119343. <https://doi.org/10.1016/j.ijpharm.2020.119343>.
- 847 Armstrong, N.A., Hainesnu.Rf, 1974. Elastic recovery and surface-area changes in compacted
848 powder systems. *Powder Technol.* 9, 287-290. [https://doi.org/10.1016/0032-5910\(74\)80054-9](https://doi.org/10.1016/0032-5910(74)80054-9).
- 849 Bekaert, B., Penne, L., Grymonpre, W., Van Snick, B., Dhondt, J., Boeckx, J., Vogeleer, J., De
850 Beer, T., Vervaeet, C., Vanhoorne, V., 2021. Determination of a quantitative relationship between
851 material properties, process settings and screw feeding behavior via multivariate data-analysis.
852 *Int. J. Pharm.* 602, 120603. <https://doi.org/10.1016/j.ijpharm.2021.120603>.
- 853 Benedetti, A., Khoo, J., Sharma, S., Facco, P., Barolo, M., Zomer, S., 2019. Data analytics on raw
854 material properties to accelerate pharmaceutical drug development. *Int. J. Pharm.* 563, 122-134.
855 <https://doi.org/10.1016/j.ijpharm.2019.04.002>.
- 856 Berkenkemper, S., Kleinebudde, P., 2022. Compressibility analysis as robust in-die compression
857 analysis for describing tableting behaviour. *RPS Pharmacy and Pharmacology Reports* 1, 1-7.
858 <https://doi.org/10.1093/rpsppr/rqac004>.
- 859 Berkenkemper, S., Klinken, S., Kleinebudde, P., 2023a. Investigating compressibility descriptors
860 for binary mixtures of different deformation behavior. *Powder Technol.*, 118571.
861 <https://doi.org/10.1016/j.powtec.2023.118571>.
- 862 Berkenkemper, S., Klinken, S., Kleinebudde, P., 2023b. Multivariate data analysis to evaluate
863 commonly used compression descriptors. *Int. J. Pharm.* 637, 122890.
864 <https://doi.org/10.1016/j.ijpharm.2023.122890>.
- 865 Bolhuis, G.K., Engelhart, J.J.P., Eissens, A.C., 2009. Compaction properties of isomalt. *Eur. J.*
866 *Pharm. Biopharm.* 72, 621-625. <https://doi.org/10.1016/j.ejpb.2009.03.005>.
- 867 Bourduche, F., Sanchez-Ballester, N.M., Bataille, B., Lefevre, P., Sharkawi, T., 2020. Structure-
868 Property Relationship of Amorphous Maltitol as Tableting Excipient. *AAPS PharmSciTech* 21,
869 281. <https://doi.org/10.1208/s12249-020-01824-8>.
- 870 Caccavo, D., Lamberti, G., Barba, A.A., Abrahmsen-Alami, S., Viriden, A., Larsson, A., 2017.
871 Effects of HPMC substituent pattern on water up-take, polymer and drug release: An experimental
872 and modelling study. *Int. J. Pharm.* 528, 705-713. <https://doi.org/10.1016/j.ijpharm.2017.06.064>.
- 873 Carlin, B., 2008. Direct Compression and the Role of Filler-binders, in: Augsburger, L.L., Hoag,
874 S.W. (Eds.), *Pharmaceutical Dosage Forms: Tablets*. Taylor & Francis Group, Boca Raton, pp.
875 173-216.
- 876 Carlin, B., 2018. The Role of Excipients in Quality by Design (QbD), in: Schlindwein, W.,
877 Gibson, M. (Eds.), *Pharmaceutical Quality by Design: A Practical Approach*. John Wiley & Sons
878 Ltd., New Jersey, pp. 97-116.

- 879 Casahoursat, L., Lemagnen, G., Larrouture, D., 1988. The use of stress relaxation trials to
880 characterize tablet capping. *Drug Dev. Ind. Pharm.* 14, 2179-2199.
881 <https://doi.org/10.3109/03639048809152010>.
- 882 Cirin-Varadan, S., Duris, J., Mirkovic, M., Ivanovic, M., Parojcic, J., Aleksic, I., 2022.
883 Comparative evaluation of mechanical properties of lactose-based excipients co-processed with
884 lipophilic glycerides as meltable binders. *J. Drug Deliv. Sci. Technol.* 67, 102981.
885 <https://doi.org/10.1016/j.jddst.2021.102981>.
- 886 Clayton, J., 2019. An Introduction to Powder Characterization, in: Narang, A.S., Badawy, S.I.F.
887 (Eds.), *Handbook of Pharmaceutical Wet Granulation: Theory and Practice in a Quality by Design*
888 *Paradigm*. Academic Press, Cambridge, MA, USA, pp. 569-613.
- 889 Colombo, P., Santi, P., Siepmann, J., Colombo, G., Sonvico, F., Rossi, A., Strusi, L., 2008.
890 Swellable and rigid matrices: Controlled release matrices with cellulose ethers, in: Augsburger,
891 L.L., Hoag, S.W. (Eds.), *Pharmaceutical Dosage Forms: Tablets*. Taylor & Francis Group, Boca
892 Raton, pp. 433-468.
- 893 Dai, S.Y., Xu, B., Zhang, Z.Q., Yu, J.Q., Wang, F., Shi, X.Y., Qiao, Y.J., 2019. A compression
894 behavior classification system of pharmaceutical powders for accelerating direct compression
895 tablet formulation design. *Int. J. Pharm.* 572, 118742.
896 <https://doi.org/10.1016/j.ijpharm.2019.118742>.
- 897 Dave, V.S., Saoji, S.D., Raut, N.A., Haware, R.V., 2015. Excipient Variability and Its Impact on
898 Dosage Form Functionality. *J. Pharm. Sci.* 104, 906-915. <https://doi.org/10.1002/jps.24299>.
- 899 David, S.T., Augsburger, L.L., 1977. Plastic flow during compression of directly compressible
900 fillers and its effect on tablet strength. *J. Pharm. Sci.* 66, 155-159.
901 <https://doi.org/10.1002/jps.2600660205>.
- 902 de Backere, C., De Beer, T., Vervaet, C., Vanhoorne, V., 2022. Effect of feed frame on lubricant
903 sensitivity during upscaling from a compaction simulator to a rotary tablet press. *Int. J. Pharm.*
904 616, 121562. <https://doi.org/10.1016/j.ijpharm.2022.121562>.
- 905 Desbois, L., Tchoreloff, P., Mazel, V., 2022. Use of jump-tests for the characterization of the
906 viscoplastic behavior of pharmaceutical powders during compaction. *Powder Technol.* 404,
907 117406. <https://doi.org/10.1016/j.powtec.2022.117406>.
- 908 Dhondt, J., Bertels, J., Kumar, A., Van Hauwermeiren, D., Ryckaert, A., Van Snick, B.,
909 Klingeleers, D., Vervaet, C., De Beer, T., 2022. A multivariate formulation and process
910 development platform for direct compression. *Int. J. Pharm.* 623, 121962.
911 <https://doi.org/10.1016/j.ijpharm.2022.121962>.
- 912 Duckworth, W., 1953. Discussion of Ryshkewitch Paper. *J. Am. Ceram. Soc.* 36, 68.
- 913 Escotet-Espinoza, M.S., Moghtadernejad, S., Scicolone, J., Wang, Y.F., Pereira, G., Schafer, E.,
914 Vigh, T., Klingeleers, D., Ierapetritou, M., Muzzio, F.J., 2018. Using a material property library
915 to find surrogate materials for pharmaceutical process development. *Powder Technol.* 339, 659-
916 676. <https://doi.org/10.1016/j.powtec.2018.08.042>.
- 917 Fell, J., Newton, J., 1970. Determination of tablet strength by the diametral-compression test. *J.*
918 *Pharm. Sci.* 59, 688-691. <https://doi.org/10.1002/jps.2600590523>.
- 919 Garekani, H.A., Ford, J.L., Rubinstein, M.H., Rajabi-Siahboomi, A.R., 2001. Effect of
920 compression force, compression speed, and particle size on the compression properties of
921 paracetamol. *Drug Dev. Ind. Pharm.* 27, 935-942. <https://doi.org/10.1081/ddc-100107674>.

- 922 Ghori, M.U., 2016. Powder Compaction: Compression Properties of Cellulose Ethers. *Br. J.*
923 *Pharm.* 1, 19-29. <https://doi.org/10.5920/bjpharm.2016.09>.
- 924 Grdesic, P., Paudel, A., Ilic, I.G., 2020. High-Molecular-Weight Hypromellose from Three
925 Different Suppliers: Effects of Compression Speed, Tableting Equipment, and Moisture on the
926 Compaction. *AAPS PharmSciTech* 21, 203. <https://doi.org/10.1208/s12249-020-01688-y>.
- 927 Grymonpre, W., Vanhoorne, V., Van Snick, B., Prudilova, B.B., Detobel, F., Remon, J.P., De
928 Beer, T., Vervaet, C., 2018. Optimizing feed frame design and tableting process parameters to
929 increase die-filling uniformity on a high-speed rotary tablet press. *Int. J. Pharm.* 548, 54-61.
930 <https://doi.org/10.1016/j.ijpharm.2018.06.047>.
- 931 Hauschild, K., Picker-Freyer, K.M., 2006. Evaluation of tableting and tablet properties of
932 Kollidon SR: The influence of moisture and mixtures with theophylline monohydrate. *Pharm.*
933 *Dev. Technol.* 11, 125-140. <https://doi.org/10.1080/10837450500464289>.
- 934 Haware, R.V., Bauer-Brandl, A., Tho, I., 2010. Comparative evaluation of the powder and
935 compression properties of various grades and brands of microcrystalline cellulose by multivariate
936 methods. *Pharm. Dev. Technol.* 15, 394-404. <https://doi.org/10.3109/10837450903262041>.
- 937 Haware, R.V., Tho, I., Bauer-Brandl, A., 2009. Multivariate analysis of relationships between
938 material properties, process parameters and tablet tensile strength for alpha-lactose monohydrates.
939 *Eur. J. Pharm. Biopharm.* 73, 424-431. <https://doi.org/10.1016/j.ejpb.2009.08.005>.
- 940 Hayashi, Y., Nakano, Y., Marumo, Y., Kumada, S., Okada, K., Onuki, Y., 2021. Application of
941 machine learning to a material library for modeling of relationships between material properties
942 and tablet properties. *Int. J. Pharm.* 609, 121158. <https://doi.org/10.1016/j.ijpharm.2021.121158>.
- 943 Heckel, R.W., 1961. Density-Pressure Relationships in Powder Compaction. *Trans. Am. Inst.*
944 221, 671-675.
- 945 Hentzschel, C.M., Sakmann, A., Leopold, C.S., 2012. Comparison of traditional and novel
946 tableting excipients: Physical and compaction properties. *Pharm. Dev. Technol.* 17, 649-653.
947 <https://doi.org/10.3109/10837450.2011.572897>.
- 948 Ilic, I., Govedarica, B., Sibanc, R., Dreu, R., Srcic, S., 2013. Deformation properties of
949 pharmaceutical excipients determined using an in-die and out-die method. *Int. J. Pharm.* 446, 6-
950 15. <https://doi.org/10.1016/j.ijpharm.2013.02.001>.
- 951 Ilic, I., Kasa, P., Dreu, R., Pintye-Hodi, K., Srcic, S., 2009. The compressibility and
952 compactibility of different types of lactose. *Drug Dev. Ind. Pharm.* 35, 1271-1280.
953 <https://doi.org/10.1080/03639040902932945>.
- 954 Ilyes, K., Casian, T., Hales, D., Borodi, G., Rus, L., Stiufiuc, R., Tomuta, I., 2021. Applying the
955 principles of Quality by Design (QbD) coupled with Multivariate Data Analysis (MVDA) in
956 establishing the impact of raw material variability for extended release tablets. *Farmacia* 69, 481-
957 497. <https://doi.org/10.31925/farmacia.2021.3.11>.
- 958 Jin, C., Zhao, L.J., Feng, Y., Hong, Y.L., Shen, L., Lin, X., 2022. Simultaneous modeling
959 prediction of three key quality attributes of tablets by powder physical properties. *Int. J. Pharm.*
960 628, 122344. <https://doi.org/10.1016/j.ijpharm.2022.122344>.
- 961 Jonat, S., Hasenzahl, S., Gray, A., Schmidt, P.C., 2005. Influence of compacted hydrophobic and
962 hydrophilic colloidal silicon dioxide on tableting properties of pharmaceutical excipients. *Drug*
963 *Dev. Ind. Pharm.* 31, 687-696. <https://doi.org/10.1080/03639040500216451>.

- 964 Kim, J.Y., Choi, D., 2022a. Control Strategy for Excipient Variability in the Quality by Design
965 Approach Using Statistical Analysis and Predictive Model: Effect of Microcrystalline Cellulose
966 Variability on Design Space. *Pharmaceutics* 14, 2416.
967 <https://doi.org/10.3390/pharmaceutics14112416>.
- 968 Kim, J.Y., Choi, D., 2022b. Quality by design approach with multivariate analysis and artificial
969 neural network models to understand and control excipient variability. *J. Pharm. Investig.*
970 <https://doi.org/10.1007/s40005-022-00608-5>.
- 971 Kosir, D., Ojstersek, T., Baumgartner, S., Vrecer, F., 2018. A study of critical functionality-
972 related characteristics of HPMC for sustained-release tablets. *Pharm. Dev. Technol.* 23, 865-873.
973 <https://doi.org/10.1080/10837450.2016.1264417>.
- 974 Larhrib, H., Wells, J.I., 1998. Compression speed on polyethylene glycol and dicalcium
975 phosphate tableted mixtures. *Int. J. Pharm.* 160, 197-206. [https://doi.org/10.1016/s0378-5173\(97\)00309-8](https://doi.org/10.1016/s0378-5173(97)00309-8).
- 977 Leane, M., Pitt, K., Reynolds, G., Mfg Classification Syst, M.C.S.W., 2015. A proposal for a drug
978 product Manufacturing Classification System (MCS) for oral solid dosage forms. *Pharm. Dev.*
979 *Technol.* 20, 12-21. <https://doi.org/10.3109/10837450.2014.954728>.
- 980 Lieberman, H.A., Lachman, L.S., J.B., 1989. *Pharmaceutical dosage forms: tablets*. Marcel
981 Dekker Inc., New York.
- 982 Maderuelo, C., Zarzuelo, A., Lanao, J.M., 2011. Critical factors in the release of drugs from
983 sustained release hydrophilic matrices. *J. Control Release* 154, 2-19.
984 <https://doi.org/10.1016/j.jconrel.2011.04.002>.
- 985 Meruva, S., Donovan, M.D., 2019. Polyethylene Oxide (PEO) Molecular Weight Effects on
986 Abuse-Deterrent Properties of Matrix Tablets. *AAPS PharmSciTech* 21, 28.
987 <https://doi.org/10.1208/s12249-019-1565-y>.
- 988 Meynard, J., Amado-Becker, F., Tchoreloff, P., Mazel, V., 2022a. Characterization of the
989 viscoelasticity of pharmaceutical tablets using impulse excitation technique. *Int. J. Pharm.* 613,
990 121410. <https://doi.org/10.1016/j.ijpharm.2021.121410>.
- 991 Meynard, J., Amado-Becker, F., Tchoreloff, P., Mazel, V., 2022b. On the complexity of
992 predicting tablet capping. *Int. J. Pharm.* 623, 121949.
993 <https://doi.org/https://doi.org/10.1016/j.ijpharm.2022.121949>.
- 994 Michaut, F., Busignies, V., Fouquereau, C., De Barochez, B.H., Leclerc, B., Tchoreloff, P., 2010.
995 Evaluation of a Rotary Tablet Press Simulator as a Tool for the Characterization of Compaction
996 Properties of Pharmaceutical Products. *J. Pharm. Sci.* 99, 2874-2885.
997 <https://doi.org/10.1002/jps.22032>.
- 998 Moreton, C., 2010. Functionality and Performance of Excipients in a Quality-by-Design World.
999 *Am. Pharm. Rev.* 12.
- 1000 Muzikova, J., Komersova, A., Lochar, V., Vildova, L., Vosoustova, B., Bartos, M., 2018.
1001 Comparative evaluation of the use of dry binders in a physical mixture or as a coprocessed dry
1002 binder in matrix tablets with extended drug release. *Acta Pharm.* 68, 295-311.
1003 <https://doi.org/10.2478/acph-2018-0030>.
- 1004 Nokhodchi, A., Ford, J.L., Rowe, P.H., Rubinstein, M.H., 1996. The effect of moisture on the
1005 Heckel and energy analysis of hydroxypropylmethylcellulose 2208 (HPMC K4M). *Journal of*

- 1006 Pharmacy and Pharmacology 48, 1122-1127. <https://doi.org/10.1111/j.2042-7158.1996.tb03906.x>.
1007
- 1008 Osamura, T., Takeuchi, Y., Onodera, R., Kitamura, M., Takahashi, Y., Tahara, K., Takeuchi, H.,
1009 2016. Characterization of tableting properties measured with a multi-functional compaction
1010 instrument for several pharmaceutical excipients and actual tablet formulations. *Int. J. Pharm.*
1011 510, 195-202. <https://doi.org/10.1016/j.ijpharm.2016.05.024>.
- 1012 Patel, S., Kaushal, A.M., Bansal, A.K., 2006. Compression physics in the formulation
1013 development of tablets. *Critical Reviews in Therapeutic Drug Carrier Systems* 23, 1-65.
- 1014 Paul, S., Sun, C.C., 2017. Gaining insight into tablet capping tendency from compaction
1015 simulation. *Int. J. Pharm.* 524, 111-120. <https://doi.org/10.1016/j.ijpharm.2017.03.073>.
- 1016 Picker, K.M., 2001. Time dependence of elastic recovery for characterization of tableting
1017 materials. *Pharm. Dev. Technol.* 6, 61-70. <https://doi.org/10.1081/pdt-100000014>.
- 1018 Pitt, K.G., Heasley, M.G., 2013. Determination of the tensile strength of elongated tablets. *Powder
1019 Technol.* 238, 169-175. <https://doi.org/10.1016/j.powtec.2011.12.060>.
- 1020 Podczek, F., 1998. Particle-particle adhesion in pharmaceutical powder handling. Imperial
1021 College Press, London.
- 1022 Podczek, F., 2012. Methods for the practical determination of the mechanical strength of tablets-
1023 From empiricism to science. *Int. J. Pharm.* 436, 214-232.
1024 <https://doi.org/10.1016/j.ijpharm.2012.06.059>.
- 1025 Portier, C., Vigh, T., Di Pretoro, G., Leys, J., Klingeleers, D., De Beer, T., Vervaet, C.,
1026 Vanhoorne, V., 2021. Continuous twin screw granulation: Impact of microcrystalline cellulose
1027 batch-to-batch variability during granulation and drying - A QbD approach. *Int. J. Pharm.: X*, 3,
1028 100077. <https://doi.org/10.1016/j.ijpx.2021.100077>.
- 1029 Reynolds, G.K., Campbell, J.I., Roberts, R.J., 2017. A compressibility based model for predicting
1030 the tensile strength of directly compressed pharmaceutical powder mixtures. *Int. J. Pharm.* 531,
1031 215-224. <https://doi.org/10.1016/j.ijpharm.2017.08.075>.
- 1032 Roberts, R.J., Rowe, R.C., 1985. The effect of punch velocity on the compaction of a variety of
1033 materials. *Journal of Pharmacy and Pharmacology* 37, 377-384. <https://doi.org/10.1111/j.2042-7158.1985.tb03019.x>.
1034
- 1035 Roopwani, R., Buckner, I.S., 2021. Understanding Deformation Behavior and Compression
1036 Speed Effect in Gabapentin Compacts. *J. Pharm. Sci.* 110, 2157-2166.
1037 <https://doi.org/10.1016/j.xphs.2020.12.021>.
- 1038 Rue, P.J., Rees, J.E., 1978. Limitations of the Heckel relation for predicting powder compaction
1039 mechanisms. *J Pharm Pharmacol* 30, 642-643. <https://doi.org/10.1111/j.2042-7158.1978.tb13347.x>.
1040
- 1041 Sonnergaard, J.M., 1999. A critical evaluation of the Heckel equation. *Int. J. Pharm.* 193, 63-71.
1042 [https://doi.org/10.1016/s0378-5173\(99\)00319-1](https://doi.org/10.1016/s0378-5173(99)00319-1).
- 1043 Sousa, A.S., Serra, J., Esteves, C., Costa, R., Ribeiro, A.J., 2022. A quality by design approach
1044 in oral extended release drug delivery systems: where we are and where we are going? *J. Pharm.
1045 Investig.* <https://doi.org/10.1007/s40005-022-00603-w>.

- 1046 Sun, C.C., 2016. A classification system for tableting behaviors of binary powder mixtures. Asian
1047 J. Pharm. Sci. 11, 486-491. <https://doi.org/10.1016/j.ajps.2015.11.122>.
- 1048 Takeuchi, H., Nagira, S., Yamamoto, H., Kawashima, Y., 2004. Die wall pressure measurement
1049 for evaluation of compaction property of pharmaceutical materials. Int. J. Pharm. 274, 131-138.
1050 <https://doi.org/10.1016/j.ijpharm.2004.01.008>.
- 1051 Thakkar, S., Sharma, K., Khurana, S., Bansal, A.K., 2016. Excipients and their functionality for
1052 enabling technologies in oral dosage forms, in: Koo, O.M.Y. (Ed.), Pharmaceutical Excipients:
1053 Properties, Functionality, and Applications in Research and Industry. John Wiley & Sons, Inc.,
1054 New Jersey, pp. 97-143.
- 1055 Thoorens, G., Krier, F., Rozet, E., Carlin, B., Evrard, B., 2015. Understanding the impact of
1056 microcrystalline cellulose physicochemical properties on tableability. Int. J. Pharm. 490, 47-54.
1057 <https://doi.org/10.1016/j.ijpharm.2015.05.026>.
- 1058 Timmins, P., Pygall, S., Melia, C.D., 2014. Hydrophilic Matrix Tablets for Oral Controlled
1059 Release. Springer-Verlag, New York.
- 1060 Tobyn, M., Ferreira, A.P., Lightfoot, J., Martin, E.B., Ghimire, M., Vesey, C., Kasuboski-
1061 Freeman, A., Rajabi-Siahboomi, A., 2018. Multivariate analysis as a method to understand
1062 variability in a complex excipient, and its contribution to formulation performance. Pharm. Dev.
1063 Technol. 23, 1146-1155. <https://doi.org/10.1080/10837450.2018.1534862>.
- 1064 USP 40-NF 35, 2017. Chapter <1062> Tablet Compression Characterization. The United States
1065 Pharmacopeia and National Formulary. US Pharmacopeial Convention, Rockville.
- 1066 Uzundu, B., Leung, L.Y., Mao, C., Yang, C.Y., 2018. A mechanistic study on tablet ejection force
1067 and its sensitivity to lubrication for pharmaceutical powders. Int. J. Pharm. 543, 234-244.
1068 <https://doi.org/10.1016/j.ijpharm.2018.03.064>.
- 1069 Van Snick, B., Dhondt, J., Pandelaere, K., Bertels, J., Mertens, R., Klingeleers, D., Di Pretoro,
1070 G., Remon, J.P., Vervaet, C., De Beer, T., Vanhoorne, V., 2018a. A multivariate raw material
1071 property database to facilitate drug product development and enable in-silico design of
1072 pharmaceutical dry powder processes. Int. J. Pharm. 549, 415-435.
1073 <https://doi.org/10.1016/j.ijpharm.2018.08.014>.
- 1074 Van Snick, B., Grymonpre, W., Dhondt, J., Pandelaere, K., Di Pretoro, G., Remon, J.P., De Beer,
1075 T., Vervaet, C., Vanhoorne, V., 2018b. Impact of blend properties on die filling during tableting.
1076 Int. J. Pharm. 549, 476-488. <https://doi.org/10.1016/j.ijpharm.2018.08.015>.
- 1077 Van Snick, B., Kumar, A., Verstraeten, M., Pandelaere, K., Dhondt, J., Di Pretoro, G., De Beer,
1078 T., Vervaet, C., Vanhoorne, V., 2019. Impact of material properties and process variables on the
1079 residence time distribution in twin screw feeding equipment. Int. J. Pharm. 556, 200-216.
1080 <https://doi.org/10.1016/j.ijpharm.2018.11.076>.
- 1081 Vanhoorne, V., Vervaet, C., 2020. Recent progress in continuous manufacturing of oral solid
1082 dosage forms. Int. J. Pharm. 579, 119194. <https://doi.org/10.1016/j.ijpharm.2020.119194>.
- 1083 Vanza, J.D., Patel, R.B., Dave, R.R., Patel, M.R., 2020. Polyethylene oxide and its controlled
1084 release properties in hydrophilic matrix tablets for oral administration. Pharm. Dev. Technol. 25,
1085 1169-1187. <https://doi.org/10.1080/10837450.2020.1808015>.
- 1086 Vreeman, G., Sun, C.C., 2021. Mean yield pressure from the in-die Heckel analysis is a reliable
1087 plasticity parameter. Int. J. Pharm.: X. 3, 100094. <https://doi.org/10.1016/j.ijpx.2021.100094>.

- 1088 Vreeman, G., Sun, C.C., 2022a. Air entrapment during tablet compression - Diagnosis, impact on
1089 tableting performance, and mitigation strategies. *Int. J. Pharm.* 615, 121514.
1090 <https://doi.org/10.1016/j.ijpharm.2022.121514>.
- 1091 Vreeman, G., Sun, C.C., 2022b. A powder tableting equation. *Powder Technol.* 408, 117709.
1092 <https://doi.org/10.1016/j.powtec.2022.117709>.
- 1093 Wan, S.L., Dai, C.Y., Bai, Y.L., Xie, W.Y., Guan, T.B., Sun, H.M., Wang, B.C., 2021.
1094 Application of Multivariate Methods to Evaluate Differential Material Attributes of HPMC from
1095 Different Sources. *ACS Omega* 6, 28598-28610. <https://doi.org/10.1021/acsomega.1c03009>.
- 1096 Wang, T., Ibrahim, A., Hoag, S.W., 2020. Understanding the impact of magnesium stearate
1097 variability on tableting performance using a multivariate modeling approach. *Pharm. Dev.*
1098 *Technol.* 25, 76-88. <https://doi.org/10.1080/10837450.2019.1673774>.
- 1099 White, L.R., Molloy, M., Shaw, R.J., Reynolds, G.K., 2022. System model driven selection of
1100 robust tablet manufacturing processes based on drug loading and formulation physical attributes.
1101 *Eur. J. Pharm. Sci.* 172, 106140. <https://doi.org/10.1016/j.ejps.2022.106140>.
- 1102 Worku, Z.A., Kumar, D., Gomes, J.V., He, Y.L., Glennon, B., Ramisetty, K.A., Rasmuson, A.C.,
1103 O'Connell, P., Gallagher, K.H., Woods, T., Shastri, N.R., Healy, A.M., 2017. Modelling and
1104 understanding powder flow properties and compactability of selected active pharmaceutical
1105 ingredients, excipients and physical mixtures from critical material properties. *Int. J. Pharm.* 531,
1106 191-204. <https://doi.org/10.1016/j.ijpharm.2017.08.063>.
- 1107 Yang, L.B., Venkatesh, G., Fassihi, R., 1996. Characterization of compressibility and
1108 compactibility of poly(ethylene oxide) polymers for modified release application by compaction
1109 simulator. *J. Pharm. Sci.* 85, 1085-1090. <https://doi.org/10.1021/js960039v>.
- 1110 Yost, E., Mazel, V., Sluga, K.K., Nagapudi, K., Muliadi, A.R., 2022. Beyond Brittle/Ductile
1111 Classification: Applying Proper Constitutive Mechanical Metrics to Understand the Compression
1112 Characteristics of Pharmaceutical Materials. *J. Pharm. Sci.* 111, 1984-1991.
1113 <https://doi.org/10.1016/j.xphs.2022.01.004>.
- 1114 Yu, D.Y., Seelam, R.R., Zhang, F., Byrn, S.R., Hoag, S.W., 2021a. Evaluation of tableting
1115 performance of Poly (ethylene oxide) in abuse-deterrent formulations using compaction
1116 simulation studies. *J. Pharm. Sci.* 110, 2789-2799. <https://doi.org/10.1016/j.xphs.2021.03.008>.
- 1117 Yu, Y.T., Zhao, L.J., Lin, X., Wang, Y.J., Du, R.F., Feng, Y., 2021b. Research on the powder
1118 classification and the key parameters affecting tablet qualities for direct compaction based on
1119 powder functional properties. *Adv. Powder Technol.* 32, 565-581.
1120 <https://doi.org/10.1016/j.appt.2021.01.002>.
- 1121 Zarnpi, P., Flanagan, T., Meehan, E., Mann, J., Fotaki, N., 2020. Impact of Magnesium Stearate
1122 Presence and Variability on Drug Apparent Solubility Based on Drug Physicochemical
1123 Properties. *AAPS J.* 22, 75. <https://doi.org/10.1208/s12248-020-00449-w>.
- 1124 Zhang, Y., Law, Y., Chakrabarti, S., 2003. Physical properties and compact analysis of commonly
1125 used direct compression binders. *AAPS PharmSciTech* 4, 489-499.
1126 <https://doi.org/10.1208/pt040462>.
- 1127 Zhang, Y., Xu, B., Wang, X., Dai, S.Y., Shi, X.Y., Qiao, Y.J., 2019. Optimal Selection of
1128 Incoming Materials from the Inventory for Achieving the Target Drug Release Profile of High
1129 Drug Load Sustained-Release Matrix Tablet. *AAPS PharmSciTech* 20, 76.
1130 <https://doi.org/10.1208/s12249-018-1268-9>.

1131 Zhang, Y., Xu, B., Wang, X., Dai, S.Y., Sun, F., Ma, Q., Shi, X.Y., Qiao, Y.J., 2018. Setting up
1132 multivariate specifications on critical raw material attributes to ensure consistent drug dissolution
1133 from high drug-load sustained-release matrix tablet. *Drug Dev. Ind. Pharm.* 44, 1733-1743.
1134 <https://doi.org/10.1080/03639045.2018.1492608>.

1135 Zhao, H.Y., Zhao, L.J., Lin, X., Shen, L., 2022. An update on microcrystalline cellulose in direct
1136 compression: Functionality, critical material attributes, and co-processed excipients. *Carbohydr.*
1137 *Polym.* 278, 118968. <https://doi.org/10.1016/j.carbpol.2021.118968>.

1138 Zhou, D.L., Law, D., Reynolds, J., Davis, L., Smith, C., Torres, J.L., Dave, V., Gopinathan, N.,
1139 Hernandez, D.T., Springman, M.K., Zhou, C.C., 2014. Understanding and Managing the Impact
1140 of HPMC Variability on Drug Release from Controlled Release Formulations. *J. Pharm. Sci.* 103,
1141 1664-1672. <https://doi.org/10.1002/jps.23953>.

1142

1143 **CRedit authorship contribution statement**

1144 **Ana Sofia Sousa:** Conceptualization, Methodology, Investigation, Writing – original
1145 draft, Visualization.

1146 **João Serra:** Conceptualization, Supervision.

1147 **Catarina Esteves:** Writing – review & editing.

1148 **Ricardo Costa:** Conceptualization, Writing – review & editing.

1149 **António José Ribeiro:** Conceptualization, Writing – review & editing, Supervision.

1150

1151

1152 **Declaration of interests**

1153

1154 The authors declare that they have no known competing financial interests or personal
1155 relationships that could have appeared to influence the work reported in this paper.

1156

1157 The authors declare the following financial interests/personal relationships which may be
1158 considered as potential competing interests:

1159

1160

1161

1162

1163

1164

1165

1166

Figure captions

1167 Fig. 9. USP <1062> tablet compression characterization based on the relationships
1168 between tensile strength, solid fraction, and compaction pressure.

1169 Fig. 10. Particle size analysis of the excipients: percentile values of Dv10, Dv50 and Dv90
1170 (a), dspan (b) and particle size distribution (c).

1171 Fig. 11. Compressibility (a), tableability (b) and compactibility (c) profiles of the
1172 investigated excipients at 80 rpm. The solid lines and markers represent the polymers and
1173 the open markers and dashed lines represent the diluents.

1174 Fig. 12. Scatterplot matrix of excipient variables. The red ellipses indicate the 95%
1175 confidence density ellipses. The blue significance circles show the correlations. Each
1176 marker represents one excipient at a given compaction pressure at 80 rpm.

1177 Fig. 13. PCA scree plot and percentage of the cumulative variance in the data.


1178 Fig. 14. PCA based on the first two components: (a) loading scatter plot and (b) score
1179 scatter plot. The colored areas indicate the 95% confidence ellipses.

1180 Fig. 15. Plot of partial contribution of excipient variables on PCA.

1181 Fig. 16. PCA biplot of excipient samples and explanatory variables - PC2 against PC1.

1182

1183



1184